

Université de Montréal

**Eye Disease and Mobility Limitations in Older Adults**

par  
Mihaela-Luminita Popescu

Département d'ophtalmologie  
Faculté de médecine

Mémoire présenté à la Faculté des études supérieures  
en vue de l'obtention du grade de Maîtrise ès sciences  
en Sciences Biomédicales

© Décembre, 2010

Université de Montréal  
Faculté des études supérieures

Cette thèse intitulée:

**Eye Disease and Mobility Limitations in Older Adults**

Présentée par:  
Mihaela-Luminita Popescu

a été évaluée par un jury composé des personnes suivantes :

Mark Lesk, M.D., président-rapporteur  
Ellen E. Freeman, Ph.D., directrice de recherche  
Olga Overbury, Ph.D., examinatrice externe

## RÉSUMÉ

**Objectif:** Évaluer les défis de la mobilité chez les personnes âgées atteintes de dégénérescence maculaire liée à l'âge (DMLA), de glaucome ou de dystrophie cornéenne de Fuchs et les comparer avec les personnes âgées n'ayant pas de maladie oculaire.

**Devis:** Étude transversale de population hospitalière

**Participants:** 253 participants (61 avec la DMLA, 45 avec la dystrophie cornéenne de Fuchs, 79 avec le glaucome et 68 contrôles)

**Méthodes:** Nous avons recruté les patients parmi ceux qui se font soigner dans les cliniques d'ophtalmologie de l'Hôpital Maisonneuve-Rosemont (Montréal, Canada) de septembre 2009 à octobre 2010. Les patients atteints de la DMLA ou de la maladie de Fuchs ont une acuité visuelle inférieure à 20/40 dans les deux yeux, tandis que les patients avec du glaucome ont un champ visuel dans le pire œil inférieur ou égal à -4dB. Les patients contrôles, qui ont été recrutés à partir des mêmes cliniques, ont une acuité visuelle et un champ visuel normaux. Nous avons colligé des données concernant la mobilité à partir des questionnaires (aire de mobilité et chutes) et des tests (test de l'équilibre monopodal, timed Up and Go (TUG) test). Pour mesurer la fonction visuelle nous avons mesuré l'acuité visuelle, la sensibilité au contraste et le champ visuel. Nous avons également révisé le dossier médical. Pour les analyses statistiques nous avons utilisé les régressions linéaire et logistique.

**Critères de jugement principaux:** aire de mobilité, équilibre, test timed Up and Go, chutes

**Résultats:** Les trois maladies oculaires ont été associées à des patrons différents de limitation de la mobilité. Les patients atteints de glaucome ont eu le type le plus sévère de restriction de mobilité; ils ont une aire de mobilité plus réduite, des scores plus bas au test TUG et ils sont plus enclins à avoir un équilibre faible et à faire plus de chutes que les contrôles ( $p < 0.05$ ). De plus, comparativement aux contrôles, les patients ayant de la DMLA ou la dystrophie cornéenne de Fuchs ont eu une aire de mobilité réduite ( $p < 0.05$ ). Les chutes n'ont pas été associées aux maladies oculaires dans cette étude.

**Conclusions:** Nos résultats suggèrent que les maladies oculaires, et surtout le glaucome, limitent la mobilité chez les personnes âgées. De futures études sont nécessaires pour évaluer l'impact d'une mobilité restreinte chez cette population pour pouvoir envisager des interventions ciblées qui pourraient les aider à maintenir leur indépendance le plus longtemps possible.

**Mots-clés:** aire de mobilité, maladie oculaire, mobilité

## ABSTRACT

**Objective:** To examine the extent of mobility limitations in patients with age-related macular degeneration (AMD), glaucoma, or Fuchs corneal dystrophy as compared to a control group of older adults with good vision.

**Design:** Cross-sectional hospital-based study

**Participants:** 253 people (61 with AMD, 45 with Fuchs, 79 with glaucoma, and 68 controls)

**Methods:** Patients were recruited from the ophthalmology clinic of Maisonneuve-Rosemont Hospital (Montreal, Canada) from September 2009 until October 2010. Patients with AMD and Fuchs had to have visual acuity in the better eye of worse than 20/40 while patients with glaucoma had to have visual field deficit in their worse eye of at least -4dB. Control patients who had normal visual acuity and visual field were recruited from the same clinic. Questionnaire (life space and falls) and performance-based (one-legged balance test, timed Up and Go (TUG) test) mobility data were collected, visual acuity, contrast sensitivity, and visual field were assessed, and the medical record was reviewed. Linear and logistic regression were used.

**Main Outcome Measures:** Life space, balance, timed Up and Go, falls

**Results:** The three eye diseases were associated with different patterns of mobility limitations. Patients with glaucoma had the most types of mobility limitations as they had reduced life space, had worse TUG scores, and were more likely to have poor balance than the control group ( $p < 0.05$ ). Compared to controls, patients with AMD or Fuchs corneal dystrophy had reduced life space ( $p < 0.05$ ). Falls were not related to eye disease in this study.

**Conclusions:** Our results suggest that eye diseases, especially glaucoma, restrain the mobility of older people. It is important to further explore the impact of eye disease on mobility in this population in order to develop interventions that would help affected older adults maintain their independence.

**Key-words:** life space, eye disease, mobility

## TABLE OF CONTENTS

|  |     |
|--|-----|
| <b>Résumé</b> .....  | iii |
| <b>Abstract</b> .....  | v   |
| <b>Table of contents</b> .....   | vii |
| <b>List of tables</b> .....  | x   |
| <b>List of figures</b> .....   | xi  |
| <b>List of abbreviations</b> .....                                     | xii |
| <b>Acknowledgments</b> .....   | xiv |
| <br>   |     |
| <b>CHAPTER I INTRODUCTION</b> .....                                    | 1   |
| <b>I.1. Mobility in Older Adults</b> .....                             | 1   |
| <b>I.2. Specific Objectives and Significance</b> .....                 | 1   |
| <b>I.3. Organization of the Thesis</b> .....                           | 2   |
| <br>   |     |
| <b>CHAPTER II LITERATURE REVIEW</b> .....                              | 4   |
| <b>II.1. Aging in Canada</b> .....                                     | 4   |
| <b>II. 2. Consequences of Mobility Loss in Older Adults</b> .....      | 4   |
| <b>II.3. Prevention of Mobility Loss in Older Adults</b> .....         | 4   |
| II.3.1. Exercise-based Interventions .....                             | 5   |
| II.3.2. Interventions for those with Impaired Vision .....             | 5   |
| <b>II.4. Measurement of Mobility</b> .....                             | 6   |
| II.4.a. Life-space Assessment .....                                    | 7   |
| II.4.b. “Timed Up and Go” Test .....                                   | 10  |
| II.4.c. Balance – One Leg Standing .....                               | 11  |
| II.4.d. Falls .....  | 12  |
| II.4.e. Other Mobility Measures .....                                  | 12  |
| <b>II.5. Non-visual Risk Factors of Mobility Loss in Old Age</b> ..... | 14  |
| <b>II.6. Description of Three Eye Diseases</b> .....                   | 14  |
| II.6.1. Glaucoma .....   | 14  |
| II.6.2. Age-Related Macular Degeneration .....                         | 15  |

|  |           |
|--|-----------|
| II.6.3. Fuchs Corneal Dystrophy .....                                  | 16        |
| <b>II.7. Measurement of Visual Function Relevant to Mobility .....</b> | <b>17</b> |
| II.7.1. Visual Acuity .....  | 17        |
| II.7.2. Contrast Sensitivity .....                                     | 18        |
| II.7.3. Visual Fields .....  | 18        |
| <b>II.8. Eye Disease and Mobility Loss.....</b>                        | <b>19</b> |
| II.8.1. Glaucoma and Mobility Loss .....                               | 19        |
| II.8.2. Age-Related Macular Degeneration and Mobility Loss ..          | 21        |
| II.8.3. Fuchs Corneal Dystrophy and Mobility Loss .....                | 23        |
| <b>CHAPTER III      METHODS .....</b>                                  | <b>23</b> |
| III.1. Pilot Data .....  | 23        |
| III.2. Sample Size Calculation .....                                   | 23        |
| <br>   |           |
| <b>CHAPTER IV      RESULTS .....</b>                                   | <b>25</b> |
| <b>Manuscript: Eye Disease and Mobility Limitation in Older Adults</b> |           |
| IV.1. Abstract .....   | 26        |
| IV.2. Introduction .....   | 28        |
| IV.3. Methods .....  | 29        |
| IV.3.1. Study Population .....   | 29        |
| IV.3.2. Data Collection .....  | 30        |
| IV.3.3. Outcomes .....   | 32        |
| IV.3.3. Statistical Analysis .....                                     | 33        |
| IV.4. Results .....  | 34        |
| IV.5. Discussion .....   | 36        |
| IV.6. Tables .....   | 41        |
| <br>   |           |
| <b>CHAPTER V      DISCUSSION .....</b>                                 | <b>45</b> |
| V.1. Eye Disease and Mobility Loss .....                               | 45        |
| V.2. Strength and Limits of the Study .....                            | 47        |
| V.3. Clinical Implications and Future Research .....                   | 49        |



**BIBLIOGRAPHY** ..... 53

## LIST OF TABLES

### Tables in Manuscript:

|   |    |
|---|----|
| <b>Table 1:</b> Description of four study groups .....  | 41 |
| <b>Table 2:</b> Unadjusted mobility scores of four groups .....   | 42 |
| <b>Table 3:</b> Linear regression results on adjusted relationship between eye disease and continuous mobility outcomes ..... | 43 |
| <b>Table 4:</b> Logistic regression on adjusted relationship between eye disease and dichotomous mobility outcomes .....      | 44 |
| <b>Table 1:</b> Risk factors for mobility loss .....  | 50 |

## LIST OF FIGURES

|   |    |
|---|----|
| <b>Figure 1.a.:</b> Life Space Assessment – English Version ..... | 51 |
| <b>Figure 1.b.:</b> Life space Assessment – French Version .....  | 52 |

## LIST OF ABBREVIATIONS

|         |  |
|---------|--|
| ADL     | Activities of Daily Living                               |
| AMD     | Age-Related Macular Degeneration                         |
| $\beta$ | Linear Regression Coefficient                            |
| CI      | Confidence Interval                                      |
| CS      | Contrast Sensitivity                                     |
| DMS-IV  | Diagnostic and Statistical Manual of Mental Disorders IV |
| ETDRS   | Early Treatment of Diabetic Retinopathy Study            |
| FCD     | Fuchs' Corneal Dystrophy                                 |
| FDT     | Frequency Doubling Technology                            |
| HMR     | Hôpital Maisonneuve-Rosemont                             |
| IADL    | Instrumental Activities of Daily Living                  |
| k       | Kappa Statistic  |
| log     | Logarithm  |
| logMAR  | Logarithm of Minimal Angle of Resolution                 |
| LS      | Life Space   |
| LSA     | Life Space Assessment                                    |
| LSA-F   | Life Space Assessment-French version                     |
| LS-C    | Life Space Composite score                               |
| LSQ     | Life Space Questionnaire                                 |
| LVR     | Low Vision Rehabilitation                                |
| m       | Meter  |
| MD      | Mean Deviation   |
| MMSE    | Mini Mental State Exam                                   |
| n       | Number of subjects                                       |
| O&M     | Orientation and Mobility                                 |
| OR      | Odds Ratio   |
| P       | P value  |
| POAG    | Primary Open Angle Glaucoma                              |
| PPA     | Physiological Profile Assessment                         |

|               |   |
|---------------|---|
| PSD           | Pattern Standard Deviation  |
| r             | Correlation Coefficient   |
| ROC           | Receiver Operating Characteristic   |
| SD            | Standard Deviation  |
| SF-36         | Physical Functioning Scale of the Short-Form 36                           |
| SPPB          | Short Physical Performance Battery  |
| TUG           | Timed Up and Go Test  |
| VA            | Visual Acuity   |
| VF            | Visual Field  |
| VA LV VFQ-48  | Veterans Affairs Low Vision Visual Functioning Questionnaire-<br>48 items |
| WHO           | World Health Organization   |
| $\mu\text{m}$ | Micrometer  |

## ACKNOWLEDGEMENTS

I would like to express my deepest gratitude to Dr. Ellen Freeman, who started me on this path, supported and guided me all through the years that I have worked with her on my Masters project; I thank her for believing in my capacity to work independently and successfully on this project. For the way in which she generously offered her valued time, her constant encouragement, her insightful wisdom, I am personally grateful.

I would like to express my gratefulness to the members of our research group, Solmaz Moghadaszadeh and Dr. Fawzia Djafari for their considerable help and advice in conducting my project.

I would like to take this opportunity to thank for the generosity in funding to Suzanne Veronneau-Troutman and the FROUM Scholarship. I am very honoured to be the recipient of this award.

I would also like to express my gratitude to the CNIB for the financial support to conduct my master project.

*To my friends, who are my family*

*And my family, who are my friends*

## **CHAPTER I INTRODUCTION**

### **I.1. Mobility in Older Adults**

The loss of mobility is a serious concern in older adults. Mobility problems have been recognized as the most frequent cause of disability in older men and women<sup>1</sup>. Shumway-Cook et al., in a cross-sectional study of 12,769 adults from the 2001 Medicare Current Beneficiary Community Survey of respondents aged 65 and over, found that half had self-reported mobility impairment<sup>2</sup>. In 2001, Statistics Canada assessed self-reported mobility impairment in adults age 18 and older. The study revealed that mobility-related disability prevalence was 31.5% for persons aged 65 and over<sup>3</sup>.

Although there are many factors that can cause mobility loss, vision plays an important role in mobility. Poor function in visual acuity, contrast sensitivity, or visual field have been related to worse mobility outcomes such as falls<sup>4</sup>, poor balance<sup>5</sup>, and car crashes<sup>6</sup>. Yet, there are very little data on how specific eye diseases are related to mobility limitations. This knowledge is necessary so that when patients have been diagnosed with an eye disease, they know what mobility risks are associated with that disease. This knowledge will also help us to know how to better help patients with eye disease with interventions designed to enhance mobility.

### **I.2. Specific Objectives and Significance**

The present research set out to evaluate the association of eye disease with mobility limitations in patients over 65 years old. The study focused on eye diseases that are associated with age such as age-related macular degeneration, glaucoma, and Fuchs corneal dystrophy. The mobility performance of subjects with the above-mentioned eye diseases was compared to normally sighted subjects of similar age using standardized questionnaires and tests.

**This thesis has 3 major objectives:**

1. To determine the relationship between eye disease and life space
2. To determine the relationship between eye disease and performance-based measures such as one-legged balance and the timed Up and Go Test
3. To determine the relationship between eye disease and falls

There are many reasons why this research is important. First, given the fact that the Canadian population is getting older, the incidence and prevalence of age-related eye disease will increase considerably. Second, older people who develop mobility disability may go on to develop more severe disability and become a burden on the healthcare system and on their families. Third, this research could be used by clinicians and workers in the social services network to assist patients with eye disease by looking for signs of mobility difficulties so they can orient their patients toward eye rehabilitation services and programs. Moreover, the more we understand about the relationship between eye disease and mobility loss, the better we may be able to intervene to prevent that loss.

**I.3. Organization of the Thesis**

This master's thesis is composed of 5 chapters. The literature review presented in Chapter II is structured in 8 sections which describe the aging population of Canada, the consequences of mobility loss in older adults, whether mobility loss can be prevented, how mobility is typically measured, a description of the eye diseases of interest, and what we know about the eye diseases of interest and mobility loss. Chapter III will describe pilot data and sample size calculations. Chapter IV comprises an article which has been submitted for publication entitled:



“Eye Disease and Mobility Limitations in Older Adults”. Chapter V goes into greater detail on the findings and on the clinical implications of the findings.

## **CHAPTER II LITERATURE REVIEW**

### **II.1. Aging in Canada**

Most industrialized societies, including Canada and Quebec, are now facing a demographic shift toward an older population. Currently, 4,687,400 out of 33,739,900 people in Canada are aged 65 and over<sup>7</sup>. In Quebec, there are 1,075,467 adults over age 65 years from a total population of 7,828,879.<sup>8</sup>

According to demographic statistics, the percentage of people in Quebec aged 65 and over was 7% in 1971 and 14.6% in 2008. The predictions for 2031 indicate that 25% of the population will be over 65 years old. The median age ascended from 26 years in 1971 to 41 years in 2008, and is predicted to be 47 years in 2031.<sup>9</sup> The aging of the population and the greater longevity of individuals will lead to increasing numbers of older people, and also, unfortunately, greater numbers of people who suffer from age-related disease.

### **II.2. Consequences of Mobility Loss in Older Adults**

The dangers of mobility impairment are significant. Mobility disability is often the first step on the path to disability<sup>10</sup>. Mobility disability can lead to loss of independence, increased risk of cardiovascular disease<sup>11</sup>, nursing home admission<sup>12</sup>, decreased social interaction, and can increase the risk of mortality<sup>11</sup>. Therefore, it is crucial to understand the risk factors for mobility loss so that mobility loss can be prevented or delayed as long as possible.

### **II.3. Prevention of Mobility Loss in Older Adults**

There is some evidence from randomized controlled clinical trials that mobility loss can be prevented in older adults. This is significant because the results

of the present study could be used to design interventions tailored to patients with eye disease.

### **II.3. 1.Exercise-based Interventions**

A systematic review by Howe et al in 2007 examined the efficacy of exercise interventions designed to improve mobility in older people living in the community or in institutional care. They included 35 randomized or quasi-randomized clinical trials, which included 2883 participants. They concluded that exercise interventions do lead to improvements in mobility in older adults. The exercise routines with the greatest impact were those targeting gait, balance, and coordination. The authors warn that these results should be interpreted with caution due to the lack of homogeneity of the randomized clinical trials (RCTs) and the fact that some RCTs suffered from methodological limitations.<sup>13</sup>

Some randomized clinical trials have been done in long-term care facilities and have also shown exercise to benefit mobility, strength, flexibility and balance. Therefore, there is some evidence that exercise can improve mobility in community and long-term care settings. However, none of these studies included people with substantial vision loss.

### **II.3. 2.Interventions for those with Impaired Vision**

Very little research has been done to evaluate interventions to improve mobility in people with low vision. Orientation and mobility (O&M) programs are often part of low vision rehabilitation. These programs are designed to teach skills to people with low vision so that they can confidently navigate in unfamiliar surroundings or when performing tasks. However, many of these programs have been based on clinical opinion and have not been rigorously tested in RCTs. A review conducted by Virgili and Rubin only found two small quasi-randomized trials

that examined O & M programs. Neither trial found any difference between adults who received the interventions and those who did not. The goal of these rehabilitation techniques was to teach the participants new orientation and mobility skills in order to be able to cope with reduced visual data.<sup>14</sup>

There is some RCT evidence, though, of the efficacy of low vision rehabilitation on mobility. For example, an RCT by Stelmack examined mobility as a secondary outcome. This study included 126 veterans older than 70 with a primary eye diagnosis of maculopathy and a visual acuity less than 20/100 in the better seeing eye. The primary outcome measure was the change in visual reading ability. The outcomes were measured at baseline and after a 4-month follow-up period. The outpatient rehabilitation program consisted of five weekly sessions at the low-vision clinic and one home visit. A low vision therapist and optometrist provided education and counselling, correction of refractive errors, eccentric viewing training, provision of low-vision assistive device, assigned homework, and home modifications. Mobility was assessed from answers to subsets of items in the VA LV VFQ-48 (Veterans Affairs Low vision Visual Functioning Questionnaire) and Physical Functioning Scale of the Short-Form 36 (SF-36). When compared with the control group, patients in the treatment group reported improvement in mobility (difference logOR = 0.84; 95%CI = 0.58-1.10;  $p < 0.01$ ; effect size, 1.14).<sup>15</sup>

To summarize, there is some evidence that mobility loss we can be prevented or delayed, but more RCT evidence is needed in those with vision loss and for a greater diversity of mobility outcomes.

#### **II.4. Measurement of Mobility**

Generally speaking, mobility is defined as the ability to move purposely by walking, by using an assistive device, or by using transportation from one's home, to the neighborhood, and to the areas outside the town.<sup>16</sup> It is an indispensable element in maintaining independence in daily life and in preventing disability.

There are questionnaire-based and performance-based measures to assess mobility. The measures used in this project such as life-space, the timed Up and Go test, balance, and falls will be the primary focus. Other commonly used mobility measures will be then described.

#### **II.4.a. Life Space Assessment**

A global measure of mobility is life space. In 1985, May et al.<sup>17</sup> introduced the first specific spatial measure of life-space mobility. Thirty people aged 64 to 88 who were living at home, completed a life-space diary for a month. The researchers defined life space as the zone through which a person moved over a specific period of time. A zone extended from one's home to one's town or geographic region. All the data written in the diaries were afterwards converted to a life-space diameter score that revealed the dimension of each subject's mobility over a one-month period. These scores were significantly correlated with gait speed ( $r = 0.79$ ,  $p < 0.01$ ) and sway path measurements ( $r = -0.65$ ,  $p < 0.01$ ). The life space approach requires good cooperation from the participant to fill out and return the diary.

In 1990, Tinetti and Ginter<sup>18</sup> introduced the Nursing Home Life-Space Diameter as an adaptation for nursing home settings and as a measure of the extent and frequency of mobility among 25 skilled nursing facility residents. The data were collected via a questionnaire that was administered to the head nurse in each nursing home facility. The score indicates the frequency of a resident's movement within his or her room and outside the room, the unit, and the facility. A lower score was associated with decreased vision ( $p < 0.01$ ), presence of neurological conditions ( $p < 0.06$ ), and a greater need for assistance with activities of daily living ( $p < 0.01$ ).

In 1999, Stalvey et al. developed a brief, self-report questionnaire (Life-Space Questionnaire LSQ) of nine items in order to evaluate participants' life-space during the past three days preceding the interview. The study included 242 participants older than 55 years who were recruited from eye care clinics. The objective of the study was to validate the reliability of the LSQ. The nine consecutive questions ask about

concentrically larger areas 1) room in which the person sleeps, 2) area immediately outside the home, 3) area outside the home, 4) the neighbourhood, 5) area outside the neighbourhood, 6) town, 7) county, 8) state, or 9) outside the United States. Participants answered with “yes”, scored as 1 or “no”, scored as 0, to all 9 questions; final individual scores were ranging from 0 to 9, larger scores suggesting larger life space. The study concluded that, in evaluating mobility, the information provided by LSQ is not redundant in comparison with other physical measurements, since the unshared variance is about 70%. Life space was significantly associated with mental status, depressive symptoms, vision (useful field of view), driving, and mobility ( $p < 0.05$ ).<sup>19</sup> The LSQ does not account for whether the participant needed assistance.

Later, in 2003, Baker et al developed the Life Space Assessment, which goes beyond the LSQ because it takes assistance into account and because it was designed to assess life space over the last month.<sup>20</sup> This tool assesses the spatial extent of a person in a given time, the frequency of going to different life space levels, and whether the patient required assistance from a technical device or from a person. The habits of displacement were evaluated as concentric zones which expand from the place where the person sleeps to outside one's town during the month before the interview (bedroom, area outside the home, neighbourhood, outside the neighbourhood, outside the town). They defined a composite measure of life-space (LS-C) as being a combination of life space level attained, degree of independence, and frequency of attainment. Scores were calculated for each level by multiplying the life-space level, the degree of independence, and the frequency of attainment (see Figures 1 and 2 for English and French versions). At the end, the level-specific values were summed giving a score ranging from 0-120. Data were collected among 306 community-dwelling subjects aged 65 and older. The authors examined the test-retest reliability of the LSA data at baseline, after two weeks and six months respectively via telephone interview. The authors ascertained that the LSA revealed a high grade of stability at baseline and after two weeks (interclass correlation coefficient = 0.96), but it was sensitive to change after a 6-month follow-up period. Moreover, life space was strongly correlated as expected with measures of physical and mental health such as physical performance, activities of daily living (ADL),

instrumental activities of daily living (IADL), depression, self-reported health, and the number of comorbidities indicating its validity ( $p < 0.05$ ).

The LSA was then used in a larger study. The University of Alabama at Birmingham study of Aging Life Space-Assessment (LSA)<sup>21</sup> assessed the life-space over the month preceding the interview, taking into account not only the area, but also the frequency of movement and the assistance needed such as, special equipment or presence of another person. The 998 subjects were recruited among community-dwelling older adults (older than 65) and the follow-up period was 18 months. This prospective observational population-based study was designed to analyze the existence of associations between LSA and physical function (ADL, IADL), physical performance (Short Physical Performance Battery [SPPB]), cognition, depression and, sociodemographic factors. Life-space was associated with mobility, physical performance tests, transportation difficulty, mental status, and depression ( $p < 0.05$ ).

The LSA questionnaire is both valid and reliable and has been translated into French<sup>22</sup>. The English version of the questionnaire was translated and adapted to French and then the French version was back-translated in English by five bilingual users. Discrepancies were corrected. The French-Canadian version of the Life-Space Assessment (LSA-F) was then validated by 40 French-speaking participants, age 50 years and over, who had been using a power mobility device for 2-15 months. Scores on the two versions were very similar (intra-class correlation coefficient = 0.87 for LS-C).

One cross-sectional analysis has shown that visual impairment in older adults was associated with reduced life space. This study, for which 909 participants were recruited, only measured near visual acuity (at 14 inches using a standard Snellen chart), had no information on cause of vision loss, and only examined maximal life space, which can be heavily influenced by social support. The relationship between specific eye diseases and life space has not been evaluated.<sup>23</sup>

#### II.4.b. “Timed Up and Go” Test

The ability to maintain balance both while standing still and while changing directions is critical to safe mobility. One measurement commonly used to assess dynamic balance is the “timed Up and Go” (TUG) test. It is easy to administer and requires only basic mobility skills. The subject, who can use a mobility aid if necessary, is timed in seconds while rising from a chair, walking three meters, turning around, walking back and sitting back on the same chair again. The TUG test is a simple, inexpensive and broadly used method that was developed to screen basic mobility.

The initial test was developed by Mathias and colleagues<sup>24</sup> using a subjective 5-point rating scale based on the examiner’s perception of the subject’s risk of falls. This approach was later revised by Podsiadlo and Richardson<sup>25</sup> and validated among 60 elderly patients who were compared with 10 healthy elderly patients admitted to a geriatric day hospital. The authors proposed a more objective scoring system. The score was equal to the time taken in seconds to complete the test. They found that the time was reliable and correlated well with the Berg balance scale, gait speed, and limitations in activities of daily living ( $p < 0.05$ ).

A study by Shamway-Cook et al<sup>26</sup> of 30 adults over age 65 years concluded that the TUG test is a valuable tool to identify elderly people who are prone to falls, with a sensitivity of 87% and a specificity of 87%. The authors administered the TUG under 3 conditions (TUG simple, TUG cognitive - with a subtraction task and TUG manual - while carrying a full cup of water). However, they concluded that the ability to predict falls is not increased by adding a secondary task while performing the TUG test. Moreover, the TUG plus secondary task scores did not increase the ability to identify community-dwelling older adults who are prone to falls.

One cross-sectional study tried to find the optimal cut-off of the TUG test in order to discriminate between community versus long term-care residence dwellers. Bischoff et al.<sup>27</sup> conducted a study among 491 community-dwelling and institutionalized women older than 65 years and they concluded that values below 12 seconds best explained residency status (this threshold showed discriminative value



in the ROC-analysis with an area under the curve of 0.969). Extrapolating to clinical practice, they suggested that community-dwelling elders who need more than 12 seconds to complete the TUG test should receive early evaluation and intervention. Moreover, they found out that residential and mobility status were the strongest predictors of the timed up and go test ( $p < 0.001$ ) explaining 54% of the variability in TUG times.

#### **II.4.c. Balance - One Leg Standing**

The one-leg standing test is one of the balance tests most frequently used to assess postural steadiness in a static position by quantitative measurement.<sup>28</sup> The test is easy to administer; however there are many variations of the one-legged test such as opening/closing the eyes, leg selection, number of trials allowed, and number of seconds of testing. Performance on this test is associated with many adverse outcomes like falls, limitations in activities of daily living, and comorbidities such as osteoporosis.

For example, Vellas et al. conducted a 3-year longitudinal study among community-living volunteers older than age 60 years in order to examine if the one-leg standing test is a predictor for falls and injurious falls. They concluded that the inability to maintain balance on one leg for 5 seconds appears to be a significant predictor of injurious falls (relative risk = 2.13; 95% CI = 1.04, 4.34;  $p = 0.03$ ), but not to all falls. The authors cautioned that it is difficult to find a unique risk factor for falls or fall injuries since there are so many factors involved in falling.<sup>29</sup>

In a prospective study involving 1-year of follow-up conducted in Canada in 1994, Maki et al. found a relationship between decreased one-leg standing time and falls. They administered the balance test to 100 volunteers older than age 62 years and measured spontaneous postural sway, induced anterior-posterior sway, induced medial-lateral sway, anticipatory adjustments preceding volitional arm movements, timed one-leg stance, and performance on a clinical balance assessment scale. Lateral stability was found to be the single best predictor of future falling risk.<sup>30</sup>

Overall, according to Michikawa and colleagues, after reviewing almost 500 articles which focused on the one-leg standing test and its implications, there is an association between the one-leg standing test time and falls, declines in ADL, and osteoporosis. In conclusion, this test can be used as a practical tool to screen the elderly for falls risk and frailty.<sup>31</sup>

#### **II.4.d. Falls**

Falls are a major health care concern for older adults. Studies indicate that about one third of older adults living in the community fall every year.<sup>32</sup>

Frequency of falls can be assessed by simply asking the person to recall falls over the last 3, 6, or 12 months, by asking people to mail back monthly postcards reporting the occurrence of falls, or by asking people to keep a daily diary using a customized calendar. Having people keep a diary is considered the gold standard of falls assessment. Having people retrospectively recall falls will likely lead to an underestimate of falls. A 12 month recall has been shown to be better than a 3 or 6 month recall.<sup>33</sup>

Older adults who fall are at a greater risk of hospitalization<sup>34</sup>, nursing home admission<sup>35</sup>, and death<sup>36</sup>. A fall can also lead to a fear of falling, which may result in decreased mobility<sup>37</sup>. Research and strategies to prevent falls are necessary.

#### **II.4.e. Other Mobility Measures**

The Short Physical Performance Battery (SPPB)<sup>38</sup> is a composite physical performance measure which evaluates gait, balance, and lower extremity strength and endurance. The final score of this test is given by summing the scores obtained by various tests such as 1) time able to stand with feet together, in the side-by-side, semi-tandem, and tandem positions, 2) 2.44 meter walking speed (8-feet), and 3) the ability to rise from a chair 5 times without using the arms. Each task is graded from 0

to 4, with 0 being the inability to perform the task and 4 being the best performance. The composite score of SPPB ranges from 0 (worse performance) to 12 (best performance). This SPPB was described for the first time by Guralnik et al.<sup>38</sup> In a cohort of 5,174 persons aged 71 years and older, they administered the SPPB in the home and they evaluated the self-reported physical performance (ADLs, ability to walk up and down stairs one floor, and ability to walk a half a mile without help). Scores on the three performance tests of SPPB were significantly correlated ( $p < 0.01$ ). The authors concluded that the SPPB is useful to distinguish a gradient of risk for mortality, nursing-home admission and disability in older people and that information provided by self-reported and performance measurements of mobility is complementary, and that both contribute to an understanding of the functional status of older adults.

Another test sometimes used to assess mobility limitations is the ability to walk 400 meters (m) at usual pace. Chang et al.<sup>39</sup> in a longitudinal study of 21 months of follow-up found that elderly people with functional limitations have a high rate of loss of ability to walk 400m at a usual pace. They enrolled 101 community-dwelling older adults aged 75 to 85 who were mobile but at greater risk to develop future disability (baseline SPPB = 4-9). Only 62 people participated in the follow-up (the differences between those lost to follow-up and those who were being followed-up were not statistically significant). After the follow-up period, 34% of the participants developed mobility disability. They found that the time required to walk 400m at baseline is a significant predictor of mobility loss at follow-up (OR = 1.6 per 1-minute difference, 95% CI = 1.04-2.45).

The disadvantage of the SPPB and the 400m walk is that they take a longer time to administer than the other mobility measures I described. In addition, the 400m walk is difficult to administer in a hospital setting in which space is limited and safety is a concern.

## **II.5. Non-visual Risk Factors of Mobility Loss in Old Age**

There are a variety of non-visual factors that can increase the risk of mobility loss in older age. Table 1 (page 49) summarizes the most consistent non-visual risk factors listing them in the following categories: demographic, comorbid conditions, lifestyle, and psychosocial.

The goal of this study is to determine the ocular causes of mobility loss in older adults. However, this table will be used to determine the factors that may confound the relationship between eye disease and mobility loss.

## **II.6. Description of Three Eye Diseases**

The focus of this thesis is on: glaucoma, age-related macular degeneration, and Fuchs corneal dystrophy.

### **II.6.1. Glaucoma**

Glaucoma is the second leading cause of blindness in the world, according to the World Health Organization.<sup>40</sup> The term glaucoma includes several types of diseases, all being characterized by progressive loss of retinal ganglion cells leading to characteristic structural damage to the optic nerve and loss of visual field. Vision loss due to glaucoma often first affects peripheral visual field and then can progressively also affect central visual field.

Glaucoma is categorized as open-angle or closed-angle, and each of these types can be primary (when the cause is unknown) or secondary (the cause results from another disorder). A third type is congenital glaucoma.

The vision loss due to glaucoma is irreversible. In Canada, in 2002-2003, based on a self-report glaucoma study, an estimated 409,000 people were affected with glaucoma, with a prevalence of 2.7% in subjects older than 40 years and 11% in

people older than 80 years.<sup>41</sup> Moreover, this is likely to be an underestimate because other research has found that half of people with glaucoma are unaware of their disease.<sup>42</sup>

Glaucoma treatment aims to reduce the intraocular pressure. It cannot cure the condition, but it can considerably slow or temporarily stop its progress. Glaucoma can be treated with medication, laser or conventional surgery.

Topical glaucoma medication such as eye drops, eye ointments, or inserts are the most prescribed. Depending on the mechanism of action, there are many types of topical medications (miotics, beta-blockers, prostaglandins analogs, carbonic-anhydrase inhibitors and alpha-adrenergic agonists), each achieving different purposes with the goal of lowering the intraocular pressure. Oral medication can be also used for the same purpose.

The goal of laser treatment is to improve the flow or outflow of aqueous in the eye, or to reduce the production of aqueous in order to decrease intraocular pressure. There are three types of techniques: trabeculoplasty, iridotomy, or cyclophotocoagulation. The goal of surgical treatment is to facilitate the flow of eye fluid by either filtration surgery or seton surgery.

### **II.6.2. Age-Related Macular Degeneration**

Age-related macular degeneration (AMD) is the leading cause of irreversible low vision in developed countries and the leading cause of legal blindness among older people in North America. Almost one million Canadians currently have early AMD with 250,000 having an advanced form of the disease and 64,000 Canadians being blind due to AMD in 2006. The number of people suffering from AMD is expected to double by 2031.<sup>43</sup> The incidence, prevalence, and progression of all forms of AMD increase with advancing age.<sup>44</sup>

The pathological abnormalities in AMD are most pronounced in the central part of the retina, in the area centralis, particularly in the central macula, which is

responsible for seeing fine details. There are two types of AMD: non-exudative (dry) AMD and exudative (wet) AMD.

Exudative or neovascular AMD is the most damaging type of AMD. It results from abnormal proliferation of blood vessels beneath the retina in a process called choroidal neovascularization. Although it affects only 10% of those with AMD, this type is responsible for 90% of severe vision loss associated with this disorder.<sup>45</sup> Treatment options include laser photocoagulation, photodynamic therapy, or injection of intraocular vascular endothelial growth factor (VEGF) inhibitors.

Generally speaking, non-exudative AMD progresses quite slowly and is usually less severe than the exudative type. For non-exudative AMD, treatment options include the use of antioxidants and mineral supplements.<sup>46</sup>

### **II.6.3. Fuchs Corneal Dystrophy**

Fuchs corneal dystrophy (FCD) is a relatively common, bilateral, often asymmetric and slowly progressive eye disease in which the inner lining of the cornea, the endothelium, changes structure and function and results in swelling, pain and loss of vision. It is an inherited autosomal dominant disorder with incomplete penetrance that is up to 3 times more frequent in woman.<sup>47</sup>

FCD is a progressive disorder with a typical symptomatic onset in the fifth or sixth decade of life with near visual acuity being the most affected at the beginning. As an age-related eye disease, FCD will continue to increase in prevalence in our aging population. Reliable prevalence estimates of FCD are not available as population-based studies have not included FCD.

The patient's vision is usually unaffected during early stages of disease, but as the severity increases, patients experience foggy or blurred vision, first only on awakening and, then, throughout the day, eye sensitivity to light and to glare, sandy or gritty sensation when blinking and, fluctuating vision. In advanced stages, patients may experience blurriness or haziness that does not clear throughout the day, severe visual impairment and pain from epithelial blisters.

Hypertonic saline eye drops or ointments that absorb the excessive fluid out of the cornea are used to relieve symptoms of FCD in the beginning. However, the only cure for Fuchs' dystrophy is a corneal transplant (penetrating keratoplasty or deep lamellar keratoplasty). Without a corneal transplant, a patient may become blind or have severe pain and very impaired vision. Corneal transplant can result in substantially improved vision and relief of symptoms with 94% achieving a visual acuity of 6/12 or better at three months post-operation.<sup>48</sup> However, transplant rejections can occur and corneal tissue availability can be a problem.<sup>49</sup>

## **II.7. Measurements of Visual Function Relevant to Mobility**

Measures of visual function important to mobility that are affected by eye disease including visual acuity, contrast sensitivity, and visual field are described below.

### **II.7.1. Visual Acuity**

Visual acuity is the most commonly used measure of visual function. It is “a measure of the spatial resolving power of the visual system”.<sup>50</sup> Distance visual acuity is typically measured by having a person read, from a distance of 2-4 meters, a standardized chart of high-contrast letters that gradually decrease in size. Most researchers currently use the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart to measure visual acuity, which consists of 14 rows with 5 letters per row and covers a 20-fold range of letter size. The standard for normal best-corrected acuity is 20/20 (in feet), 6/6 (in meters) or 0.0 (in logMAR), although some older adults have vision much better than this level.<sup>51</sup> Visual acuity can be measured with normal correction (habitual) or with optimal correction (best-corrected) depending on the goal.

### **II.7.2. Contrast Sensitivity**

Contrast sensitivity is “the inverse of a measure of the lowest contrast, or difference in luminance across borders, an observer can detect”.<sup>50</sup> Diseases like cataract, glaucoma, macular degeneration, and multiple sclerosis often limit contrast sensitivity. Ideally, contrast sensitivity is measured in a laboratory setting using “patches of bars that vary over a wide range of sizes” allowing one to construct a contrast sensitivity function.<sup>50</sup> However, for epidemiological research on large groups of people, contrast sensitivity is typically measured using the Pelli-Robson chart which utilizes a single large letter size in which the letters gradually decrease in contrast. This chart reflects contrast sensitivity “near the peak of the contrast sensitivity function”.<sup>50</sup> Although contrast sensitivity and visual acuity are moderately correlated, contrast sensitivity does provide additional information and is often “a better predictor of performance than acuity”.<sup>50</sup>

### **II.7.3. Visual Fields**

The visual field is the “spatial extent over which the visual system is sensitive to light”.<sup>50</sup> The visual field can be divided into three regions: macular, central, and peripheral region. Many diseases, if severe, can affect the visual field. The visual field is typically measured using an automated static perimetry device in which small spots of light are shown on a uniform background in all of the locations of the visual field. The test does not involve character recognition or resolution, but only the detection of light at varying intensities. Visual field testing “is important because it is the only clinical test that evaluates vision outside the macula”, or outside the point of fixation.<sup>50</sup> Frequency-doubling technology (FDT) was developed in 1997 and allows for fast and effective detection of visual field loss. FDT utilises the mechanism described by Kelly in 1966, the frequency-doubling illusion, in which a sine wave grating of low spatial frequency undergoing counterphase flicker at high temporal



frequency appears to the observer to have double the number of bars than are actually present.<sup>50</sup>

The FDT perimeter offers two types of test patterns, screening (C-30) and threshold tests (C-20 and N-30 which detect what is the minimum contrast that will evoke a response from the patient). The C-20 presentation pattern tests the central 20° with 17 stimulus locations, made up of four 10°-targets per quadrant and a circular 5° central one. Two additional points, one presented above and the other below the horizontal midline positioned between 20° and 30° in the nasal field, are incorporated in the N-30 test. At the end of each eye examination, the fixation point is moved temporally in order to test nasal points by redirecting the fixation point 10° temporally.

FDT provides two global indices to generally summarize the visual field results for threshold tests: mean deviation (MD) and pattern standard deviation (PSD). MD represents the average sensitivity deviation from a normal healthy person of the same age. PSD indicates localized loss, showing how evenly the field loss is spread across the visual field.

The advantages of this technique are that the test is rapid, takes one minute for screening and five minutes for the threshold determination, and it is not influenced by pupil size.

The disadvantages are that patients with poor cognitive abilities can have difficulty understanding the instructions and it is less capable of discovering early scotoma in AMD patients or in discovering visual field loss in certain neuro-ophthalmologic diseases.<sup>52</sup>

## **II.8. Eye Disease and Mobility Loss**

### **II.8.1. Glaucoma and Mobility Loss**

There has been little research done examining mobility limitations in patients with glaucoma.

Turano et al compared the mobility performance of 47 glaucoma patients to normal-vision subjects who were of similar age. They evaluated 1) walking speed through a predefined course with obstacles to be avoided, 2) if the subjects reported a fall or had a fear of falling in the year preceding the evaluation, and 3) vision (visual acuity, contrast sensitivity and, monocular and binocular visual fields). They found that people with glaucoma had, on average, a reduced walking speed, orientation problems and an increased likelihood of bumping into objects, but the differences were not statistically significant when compared with people with normal vision. It is possible that this study was underpowered with only 47 patients in each group.<sup>53</sup>

In a population-based observational study, Friedman et al. investigated the relationship between glaucoma and mobility limitations. They used 1,214 people older than 74 years already enrolled in the Salisbury Eye Evaluation Project. Mobility was assessed using a predefined course which subjects had to cover as quickly and safely as possible while avoiding all obstacles, along with three other tests: climbing stairs, walking a straight 4-m course and a 30-second timed stand. They measured visual field, visual acuity and contrast sensitivity. After adjustment for demographic and health variables, they found that people with bilateral glaucoma had decreased mobility performance, walking more slowly and having more bumps on the mobility course. Walking speed through the obstacle course was 2.4 meters/minute slower for those with bilateral glaucoma compared to people without glaucoma ( $p < 0.05$ ). Moreover, people with bilateral glaucoma experienced 1.65 times the number of bumps when compared with persons without glaucoma ( $p < 0.05$ ).<sup>54</sup> How these results translate into real-world mobility difficulties is unknown.

A study conducted by Shabana et al examining 35 primary open-angle glaucoma (POAG) patients and 21 age-matched normal subjects demonstrated that individuals with POAG sway more when standing than normal individuals. Moreover, the greater sway is associated with more vision damage, indicating the existence of a visual contribution to posture at all stages of glaucoma.<sup>55</sup> These findings are consistent with those of another study conducted by Black et al in a larger sample of POAG patients. Greater sway was associated with increasing VF impairment in the better eye.<sup>56</sup>

One of the consequences of poor balance and/or an increase in bumping into things may be more frequent falls. Patients with glaucoma are at an increased risk of falls according to two studies.<sup>57, 58</sup> In a cross sectional survey among 3,654 community-dwelling older adults aged 49 or older in Australia, the frequency of falling was associated with posterior subcapsular cataract and use of nonmiotic glaucoma medication. Haymes et al. evaluated the frequency of falls (self-reported) during the year preceding the evaluation of 48 glaucoma patients when compared with 47 controls. After adjusting for age, gender, body mass index, polymedication, and better eye Humphrey Field Analyzer (HFA) MD, glaucoma patients had over 3 times the odds of falling (OR = 3.71; 95%CI = 1.14-12.05) at least once in the previous 12 months.<sup>58</sup> This very large odds ratio should be confirmed in further research.

More research is needed on how real-world mobility is impacted in people with glaucoma.

### **II.8.2. Age-Related Macular Degeneration and Mobility Loss**

Similarly, few studies were found that examined the mobility of people with AMD.

A study by Wood investigated postural stability and gait characteristics of older adults with AMD and the visual parameters (binocular high-contrast visual acuity, contrast sensitivity, and visual field) associated with postural stability and gait. This study included 80 individuals older than 59 years with an AMD diagnosis as the unique cause of vision impairment. Postural stability was assessed by asking the participant to stay as still as possible for maximum 30 seconds on foam and firm surfaces. Information on anterior-posterior and mediolateral sway was assessed during this time. Gait was evaluated by measuring stride length, double-support time, step width, and walking velocity through a 12-m mobility course at a self-selected and comfortable pace. In the separate models, contrast sensitivity, visual acuity, and visual field loss were all significantly correlated with postural stability on the foam

surface; in the multivariate model only contrast sensitivity was statistically associated with postural stability on the foam surface. None of the vision variables were correlated with sway on the firm surface.<sup>59</sup> These findings agree with those of Waterloo Vision and Mobility study conducted by Spaulding et al. which examined specific gait characteristics of AMD-patients and concluded that these patients have shorter stride length and longer time for stride and stance. In this study, Spaulding recruited 20 AMD patients and 20 age-matched controls. Gait adaptation strategies were evaluated with a 6-m path with different texture of surface: compliant, uneven, or shiny.<sup>60</sup>

A cross-sectional observational study of 166 adults conducted by Cruess et al. evaluated the burden of patients with neovascular AMD when compared with control subjects via telephone surveys. The authors used standardized questionnaires to assess general health and vision specific quality of life and also asked questions to determine the rate of accidents, falls, falls-related injuries, etc. Subjects with AMD had more than twice the need for assistance with activities of daily living ( $p = 0.013$ ) and an almost three times higher rate of falls ( $p = 0.014$ ) when compared with controls.<sup>61</sup> However, these results were not adjusted for age and since there was a very large difference in age between those with AMD and those without AMD, it is likely that these results are confounded.

Hassan et al. investigated how AMD affects mobility performance and which are the vision determinants of mobility among 21 subjects with AMD and 11 age-matched controls. Mobility was assessed by examining the walking speed on a 20-m straight, unobstructed course and then the number and type of obstacles contacted during a high-density indoor obstacle course. Vision was assessed through habitual visual acuity, contrast sensitivity, and binocular visual field. There was no difference between walking speed and obstacle contact on the mobility course between the two groups.<sup>62</sup> However, this study may have been underpowered to detect differences with such a small sample size.

Impaired vision is an important and independent risk factor for falls.<sup>63</sup> Studies have evaluated the risk of falls among patients with AMD. For example, Szabo et al conducted a study in Vancouver among 545 community-dwelling women, between

70 and 92 years old, divided into three groups: a group of 115 people with exudative AMD and two control groups, 54 community-dwelling women without exudative AMD drawn from the same community (non-AMD cohort) and 341 community-dwelling Australian women (Australian normative cohort). They evaluated the risk of falls using the short-form Physiological Profile Assessment (PPA), which provides a fall risk index score and contains five items: vision, peripheral sensation, lower limb strength, reaction time and body sway. The mean fall-risk index score in the AMD cohort (3.20) was significantly greater than that of the non-AMD cohort.<sup>64</sup>

### **II.8.3. Fuchs Corneal Dystrophy and Mobility Loss**

There are no studies that we are aware of that have looked at mobility limitations among people with Fuchs corneal dystrophy.

## **CHAPTER III METHODS**

The methods for this project are presented in detail in the manuscript in Chapter IV. Therefore, in this section, pilot data and the sample size calculations that were used to plan this study are presented.

### **III.1. Pilot Data**

Because life space had rarely been studied in patients with eye disease, we collected limited pilot data in the fall of 2008 to determine the variability of the life space scores in patients with and without AMD. Over a 3-week period, pilot data were collected on life space scores from 16 patients with AMD and 22 similarly-aged patients who did not have AMD and who had good vision. Although this is a small sample of patients, we found evidence that the AMD group had substantially

decreased LS-C scores compared to the group without AMD (average difference = 8.5, SE = 7.4). We also saw good variability in LS-C scores in our study population (range 18-110).

### **III.2. Sample Size Calculation**

We performed sample size calculations for the four outcomes of interest in order to achieve 80% power to detect associations of the following magnitudes. For the LS-C outcome, we required 64 people per group in order to detect a difference in LS-C scores of 10 assuming a SD of 20. For the TUG test, we required 64 people per group in order to detect a difference in times of 3 seconds between groups assuming a SD of 6. For the one-legged balance test, we required 49 people per group to detect a 2.6-fold difference in proportions of people with poor balance between groups (15% versus 40%). Finally, for falls, we required 58 people per group to detect a 2-fold difference in proportions of people who fell in the last year (25% versus 50%). These calculations all assume a 5% alpha and were made with the PS Power and Sample Size Program (Vanderbilt, TN, USA). Data used for these calculations are based on reasonable assumptions based on our pilot data, other literature, and what we believed to be clinically significant differences.

CHAPTER IV RESULTS

**Eye Disease and Mobility Limitations in Older Adults**

**Mihaela L. Popescu, MD<sup>1</sup>, Hélène Boisjoly, MD, MPH<sup>1,2</sup>, Heidi Schmaltz, MD<sup>3</sup>, Marie-Jeanne Kergoat, MD<sup>4</sup>, Jacqueline Rousseau, PhD<sup>4</sup>, Solmaz Moghadaszadeh, BSc<sup>1</sup>, Fawzia Djafari, MD, MSc<sup>1,2</sup>, Ellen E. Freeman, PhD<sup>1,2</sup>**

<sup>1</sup> Centre de Recherche, Hôpital Maisonneuve-Rosemont, Montréal, Canada; <sup>2</sup> Département d'ophtalmologie, Université de Montréal, Montréal, Canada; <sup>3</sup> Department of Geriatric Medicine, University of Calgary, Calgary, Canada; <sup>4</sup> Centre de Recherche, Institut universitaire de gériatrie de Montréal, Montréal, Canada

**Financial Support:**

CNIB New Investigator Grant, Toronto, Canada  
 Canadian Institutes of Health Research Grant IAP-98996, Ottawa, Canada  
 Fonds de Recherche en Santé du Québec salary award (Dr. Freeman)  
 Fonds de recherche en ophtalmologie de l'Université de Montréal salary award  
 (Dr. Popescu)

The funding organizations had no role in the design or conduct of this research.

No conflicting relationship exists for any author.

Running Head: Eye Disease and Mobility Limitations

**Reprint Address:**

Ellen Freeman, PhD  
 Hôpital Maisonneuve-Rosemont  
 Recherche ophtalmologie, CSA, RC, F131  
 5415 boulevard de l'Assomption  
 Montréal (QC) H1T 2M4  
 CANADA

## ABSTRACT

**Objective:** To examine the extent of mobility limitations in patients with age-related macular degeneration (AMD), glaucoma, or Fuchs corneal dystrophy as compared to a control group of older adults with good vision.

**Design:** Cross-sectional hospital-based study

**Participants:** 253 people (61 with AMD, 45 with Fuchs, 79 with glaucoma, and 68 controls)

**Methods:** Patients were recruited from the ophthalmology clinic of Maisonneuve-Rosemont Hospital (Montreal, Canada) from September 2009 until October 2010. Patients with AMD and Fuchs had to have visual acuity in the better eye of worse than 20/40 while patients with glaucoma had to have visual field deficit in their worse eye of at least -4dB. Control patients who had normal visual acuity and visual field were recruited from the same clinic. Questionnaire (life space and falls) and performance-based (one-legged balance test, timed Up and Go (TUG) test) mobility data were collected, visual acuity, contrast sensitivity, and visual field were assessed, and the medical record was reviewed. Linear and logistic regression were used.

**Main Outcome Measures:** Life space, balance, TUG, falls

**Results:** The three eye diseases were associated with different patterns of mobility limitations. Patients with glaucoma had the most types of mobility limitations as they had reduced life space, had worse TUG scores, and were more likely to have poor balance than the control group ( $p < 0.05$ ). Compared to controls, patients with AMD or Fuchs corneal dystrophy had reduced life space ( $p < 0.05$ ). Falls were not related to eye disease in this study.



**Conclusions:** The results suggest that eye diseases, especially glaucoma, restrain the mobility of older people. It is important to further explore the impact of eye disease on mobility in this population in order to develop interventions that would help affected older adults maintain their independence.

## INTRODUCTION

The impact of age-related eye disease on mobility is an important area of research given the aging of the population and the importance of mobility in the prevention of disability<sup>10</sup> and mortality<sup>11</sup>. Yet, we are only beginning to understand the mobility limitations of people with eye disease. Friedman et al found that people with bilateral glaucoma were slower and bumped into more objects on a mobility course but the real-world implications of these findings are not known<sup>54</sup>. Some small studies have been done on patients with age-related macular degeneration (AMD) and have mainly focused on falls and postural stability<sup>59, 61, 62</sup>. We are unaware of any studies examining the mobility problems of people with Fuchs corneal dystrophy. More research is needed on how different eye diseases are associated with a range of mobility limitations.

The first objective was to comprehensively examine several measures of real-world mobility performance (such as life space, balance, timed Up and Go test (TUG), and falls) in people with one of three common age-related conditions (AMD, Fuchs corneal dystrophy, and glaucoma) compared to a control group. These three age-related diseases were chosen because they have very different profiles of vision loss that might impact mobility in different patterns. It was hypothesized that all three eye diseases would be associated with the four mobility limitations but that diseases with a larger impact on central vision (AMD and Fuchs) would have bigger association with restricted life space whereas diseases with a larger impact on peripheral vision (glaucoma) would have bigger associations with falls, balance, and the TUG test. The second objective was to determine whether any relationships

between eye disease and mobility were primarily explained by visual acuity, contrast sensitivity, or visual field.

## **METHODS**

### **Study Population**

All participants were recruited from the ophthalmology clinics at Maisonneuve-Rosemont Hospital in Montreal, Canada, between September, 2009, and October, 2010. Three members of the research team (MP, SM, FD) reviewed patient files for eligibility each day.

All patients had to be 65 or older. Furthermore, the patients with a clinical diagnosis of AMD, Fuchs, or glaucoma had to have at least some vision loss. Specifically, the AMD and Fuchs patients had to have disease in both eyes and to have best corrected visual acuity worse than 20/40 in their better eye. Glaucoma patients had to have the disease in both eyes and had to have a visual field mean deviation worse than or equal to -4dB in their worse eye. All glaucoma types were recruited. The three groups with eye disease were allowed to have other eye diseases. Finally, the controls had to have best corrected visual acuity of 20/40 or better in the better eye and a visual field in the worse eye better than -4dB. Controls either had no current eye disease (63%) or they had non-visually impairing conditions such as early cataract (15%), early AMD (4%), ocular hypertension (5%), blepharitis (5%), or other (8%). People who had received eye surgery, laser, or an intra-vitreous injection in the last three months were enrolled after a 2-3 month delay so that their mobility would not be affected by their recovery. Patients also had to score 10 or better on the Mini-Mental State Exam Blind Version to optimize the

reliability of the collection of the self-reported data. The Blind version of the MMSE omits eight items that rely on vision and has been validated against the original version<sup>65</sup>. A score of 10 on the Blind version corresponds to a score of 18 on the original version, which was used in previous vision research on older adults<sup>66</sup>.

There were 420 patients who appeared to meet eligibility criteria from a review of the medical records. Of the 420 patients, 300 patients accepted our invitation to be in the study (71%), 101 refused (24%), and 19 (5%) were not capable of responding for themselves. Of the 300 who accepted, 253 people met final eligibility criteria including 61 with age-related macular degeneration (AMD), 79 with glaucoma, 45 with Fuchs corneal dystrophy, and 68 people without significant eye disease. Participants were paid \$10 for their participation and signed a consent form. The project was approved by the Ethics Committee at the Hospital and the research conformed to the tenets of the Declaration of Helsinki.

### **Data Collection:**

Data were collected in a 1-1.5 hour session by one of three trained research personnel. Participants first answered questions on demographics (age, gender, education), mobility, and health. Then they performed brief mobility, clinical, and vision tests. The medical chart was also reviewed.

### Mobility

Questionnaires and performance-based tasks were performed to assess four different mobility outcomes. The Life Space Assessment (LSA) was used to measure the spatial extent of participants in a given month<sup>20, 22</sup>. The LSA takes into account the

frequency of going to different life space levels (bedroom, driveway, within neighborhood, outside neighborhood but within town, out of town) and whether assistance was required to get to those levels. A composite score (LS-C, range 0-120) is calculated which combines information on the life space level, the degree of independence, and the frequency. The reliability and construct/criterion validity of this questionnaire have been published<sup>20</sup>. People were asked if they had fallen in the last year, a fall being defined as unintentionally coming to rest on the ground or on some other level. Balance was assessed using the one-legged balance test in which the person is asked to stand on the leg of choice with eyes open for up to 30 seconds<sup>29</sup>. People who cannot stand for 5 seconds on one leg are at an increased risk of having an injurious fall<sup>29</sup>. Finally, the timed “Up and Go” (TUG) test was performed in which a person is asked to rise from a seated position, walk 3 meters, and return to the seat while being timed<sup>25</sup>. On previous research studies, the TUG test was found to have good reliability and was correlated with gait speed, activities of daily living limitations, and balance<sup>25</sup>. Reasons for not doing either the balance test or the TUG test were noted (e.g. safety concern of participant or researcher, refusal for non-safety reasons such as pain).

### Health and Anthropometric Measures

Participants were asked to self-report a physician diagnosis of 13 chronic comorbid conditions (e.g. stroke, Parkinson’s, heart disease, diabetes) and whether they were currently taking benzodiazepines, a potential falls risk factor<sup>67-69</sup>. A sum of the total number of chronic conditions was used to indicate comorbidity, as has been done in previous research<sup>54</sup>. Depression was assessed using the Geriatric Depression 15-

item Scale <sup>70,71</sup>. A score of 5 or greater was used to indicate depression <sup>72</sup>. Cognitive status, as mentioned previously, was measured using the Mini-Mental State Exam Blind Version which excludes eight items that rely heavily on vision for a total maximum score of 22 <sup>65</sup>. Height and weight were measured without shoes using a Detecto balance scale with height rod (Detecto Medic, Brooklyn, NY). Body mass index was calculated as  $\text{kg/m}^2$ . Obesity was defined as a body mass index of 30  $\text{kg/m}^2$  or greater.

### Vision and Eye Disease

Binocular habitual visual acuity was measured using the ETDRS chart with illuminated light box at 2 meters or at 1 meter if the participant could not read any letters at 2 meters <sup>73, 74</sup>. Letter by letter scoring was performed with scores at 2 meters converted to scores at 1 meter by adding 15. Contrast sensitivity was measured using the Pelli-Robson chart at 1 meter for each eye <sup>75</sup>. Visual field was measured using the Humphrey FDT test for each eye <sup>76</sup>. The medical record was reviewed and information on severity of eye disease and coexisting eye disease was recorded. Those who could not perform the FDT test because of advanced eye disease had their last visual field exam results taken from the medical record.

### **Outcomes**

The LS-C and TUG scores were examined as continuous variables given the approximately normal distribution of their scores. The other outcomes were dichotomized. The balance time was dichotomized at 5 seconds due to the truncated nature of the measurement at 30 seconds and due to the previous finding that a time

of 5 seconds or less was indicative of a recent fall <sup>29</sup>. Falls were examined as having reported a fall in the last year or not.

### **Statistical Analyses**

Descriptive statistics were calculated including means, standard deviations, and percentages. Vision, demographic, health, and mobility variables were compared for the three eye disease groups and the control group using ANOVA or chi-square tests. Next, to determine if eye disease was independently associated with any of the mobility outcomes, regression was used to adjust for potential confounding. The different disease groups (AMD, glaucoma, and Fuchs dystrophy) were entered as indicator variables in the regression model with the control group as the reference. Linear regression was used to determine if LS-C or TUG scores differed for any of the eye disease groups compared to the control group after adjustment for demographic and health variables including age, gender, education, body mass index, depression, number of comorbidities, benzodiazepine use, and cognitive status. Race was not included in the regression models due to the absence of non-white patients in certain eye disease groups. The relationship between eye disease and the dichotomous outcomes (falls, balance) were examined using logistic regression.

To determine the measures of visual function primarily explaining the relationships between eye disease and mobility, the five measures of visual function (binocular visual acuity, contrast sensitivity in the better or worse eye, visual field in the better or worse eye) were entered one at a time into the model with the eye disease variable, and the visual function variable causing the maximal change in the regression

coefficients for the eye disease variables was noted. Analyses were done in Stata Version 11.0 (College Station, Texas).

## RESULTS

Two hundred fifty-three patients who resided in the community (81%), in assisted living (10%) or in a retirement home (9%) were recruited into the study. In Table 1, the demographic, visual, and health characteristics of the four groups are compared. The groups with eye disease were older than the control group ( $p < 0.001$ ). The AMD and Fuchs groups had a higher percentage of women than the glaucoma or control groups ( $p = 0.001$ ). The glaucoma group had a greater percentage of patients of African descent than the other groups, which had none to one patient of African descent. The groups with eye disease had worse cognitive, depression, and comorbidity scores ( $p < 0.001$ ) while there was no significant difference in obesity between the groups.

As expected, visual acuity and contrast sensitivity were worst in the AMD and Fuchs groups while visual field was worst in the glaucoma group ( $p < 0.001$ ) (Table 1). The binocular visual acuity in the AMD group was 0.73 logMAR (~20/90 Snellen), in the Fuchs group was 0.64 logMAR (~20/80 Snellen), in the glaucoma group was 0.33 logMAR (~20/45 Snellen), and in the control group was 0.04 logMAR (~20/20 Snellen). The glaucoma patients mainly had primary open-angle glaucoma (79%), 8% had normal tension glaucoma, 5% had secondary glaucoma, while the rest had other forms or the medical record did not specify (8%). The mean pachymetry value in the worse eye of the Fuchs patients was 691  $\mu\text{m}$  (SD = 109).



In unadjusted analyses, the three groups with eye disease had worse average life space and TUG times and were more likely to have poor balance, not to drive, and to do no regular exercise ( $p < 0.05$ ) (Table 2). There were no differences among the groups for having fallen in the last year ( $p = 0.265$ ). The presence of injurious falls and the number of falls in the last year also did not significantly differ among the groups (data not shown).

In linear or logistic regression models adjusting for demographic and health variables, all three groups with eye disease had worse life space. Patients with AMD had life space scores that were 15 points lower on average (95% CI = -23, -6) than the control patients while patients with Fuchs and glaucoma had life space scores that were 12 (95% CI = -20, -3) and 11 points (95% CI = -18,-4) lower respectively (Table 3).

Patients with glaucoma had worse scores on the TUG test and the one-legged balance test (Tables 3-4 respectively). Glaucoma patients took 1.6 seconds longer ( $p = 0.026$ ) on average to complete the TUG test and had 4.1 times the odds ( $p = 0.005$ ) of being unable to hold balance for 5 seconds compared to control patients. Patients with AMD or Fuchs did not perform significantly worse on these tests compared to controls.

None of the eye disease groups were more or less likely to fall (Table 4). Secondary analyses examining two or more falls or fall number also did not indicate associations (data not shown).

In order to determine which of the three measures of visual function explained the biggest part of the relationship between each eye disease and each mobility outcome, each measure of visual function was entered separately into the

regression models while keeping the number of observations constant between the models with and without the measure of visual function (data not shown). For life space, contrast sensitivity in the worse eye explained the biggest parts of the relationships for AMD, Fuchs, and glaucoma. For the TUG score, visual field in the better eye explained the biggest part of the relationship with glaucoma. For the balance test, contrast sensitivity in the better eye explained the biggest part of the relationship with glaucoma.

## **DISCUSSION**

All patients with vision loss had reduced mobility, but the pattern of mobility impairment differed by diagnosis. The results indicate that patients with glaucoma had the highest number of mobility limitations with reduced life space, slower TUG times, and poorer balance. Patients with AMD had the most reduced life space. The measures of visual function that explained these relationships differed depending on the mobility task. For example, the relationship between glaucoma and balance was explained mainly by contrast sensitivity while the relationship between glaucoma and the TUG time was explained mainly by visual field.

The hypothesis was partially confirmed in that AMD had the largest association with life space, but glaucoma also showed strong associations with life space. Glaucoma was related to the TUG time and to poor balance, but it was not related to falls. It was expected that diseases affecting peripheral vision would have a bigger impact on balance and falls due to prior research showing the importance of visual field on postural stability, falls, and balance<sup>56, 77, 78</sup>. Additionally, it was anticipated that the Fuchs patients would be more similar to the AMD patients.

While Fuchs can affect both central and peripheral vision, the Fuchs participants had decreased visual acuity and contrast sensitivity but only modestly decreased visual field. The Fuchs participants in the study had reduced life space, similar to the AMD participants, as expected.

This study is novel in its ability to examine a range of mobility outcomes across patients with different eye diseases compared to controls without significant vision loss. Validated measures of mobility that have been found to be associated with a range of adverse health outcomes were utilized<sup>20, 25, 29</sup>. To our knowledge, no previous studies have examined the relationships between the eye diseases of interest and life space, TUG time, or the one-legged balance test. Previous research has been done examining postural sway in glaucoma patients or AMD patients<sup>55, 56, 59</sup>. The present results for one-legged balance support these studies.

The lack of associations between the eye diseases and falls was surprising, given that various measures of visual function have been associated with falls in other research<sup>4, 57, 63, 78-80</sup>. Few studies have examined falls in a population of patients with eye disease. One study found that glaucoma patients had over three times the odds of a self-reported fall compared to controls (OR = 3.71, 95%CI = 1.14, 12.05)<sup>58</sup>. This study did not replicate this finding, possibly due to differences in the control selection. Controls in the previous study were recruited by public notices within a Health Sciences Centre, while controls in this study were patients without significant vision loss from the same ophthalmology clinic in order to be as similar as possible to the cases. In a study of AMD and falls, one study found that neovascular AMD patients were three times more likely to fall than people without AMD (p = 0.014)<sup>61</sup>. However, adjusted results for falls were not given and it is

possible that these results are affected by confounding, given the 17-year age difference between those with and without AMD. Despite the lack of an association with falls in the present data, glaucoma was associated with worse TUG times and poor balance, two mobility outcomes that are themselves related to falls or disability<sup>25, 29</sup>. It is possible that patients with eye disease have developed compensatory strategies (such as reduced life space) or gait adaptations to avoid falling<sup>60</sup>. Another possibility is significant misclassification of the self-report of falls.

Not surprisingly, other known risk factors for mobility limitations affected the outcomes of the study participants with eye disease. People whose GDS-15 scores suggested depression had worse mobility outcomes. For example, they had lower life space scores, were more likely to have poor balance, and were more likely to have fallen compared to people without depression ( $p < 0.05$ ). A large percentage (25%) of the study population met the criteria for depression using a cutoff of 5 or greater. It appears that there was a great unmet need for depression treatment in the study population. It was suggested to people whose scores indicated depression that study should consider consulting with their primary care physician about treatment options. Also, women had more mobility limitations than men as they had lower life space scores, slower TUG times, and were somewhat more likely to have poor balance ( $p = 0.086$ ) (Tables 3-4). The present data fit with prior research indicating that women have a greater incidence of mobility disability than men<sup>81</sup>. This study was not designed to examine interaction between eye disease and other factors such as depression or gender, but future research should examine whether there is a synergistic effect on mobility limitations.

Strengths of this study include the inclusion of multiple questionnaire and performance-based measures of mobility, the examination and comparison of people with different eye diseases representing different patterns of vision loss, the measurement of visual acuity, contrast sensitivity, and visual field, and the inclusion of many potential confounding factors in the analysis.

A limitation of this study is the use of self-reported data to measure the falls. The validity of the retrospective falling question was found by Cumming et al to have a correlation of 0.6 with the prospective reporting of falls with a 12-month recall being better than a shorter recall of 3 or 6 months<sup>33</sup>. Also, participants in this study come from a single hospital rather than a population-based study making the possibility of selection bias more likely. However, all of the patients with and without eye disease came from the same department of the hospital, 94% of patients live within a 1-hour drive, and the response rate of our patients was high at 71%. Finally, the Fuchs group was smaller than the other groups (n = 45) resulting in more limited power for that group. However, generally, there was good power to detect reasonably sized relationships with all mobility outcomes as the many statistically significant findings demonstrate.

Different eye diseases were found to be associated with different patterns of mobility limitations. This knowledge is relevant to those providing low vision rehabilitation services and to patients with moderate to severe eye disease and their families. Despite the great advancements being made in the treatment of age-related eye disease, millions of people are still faced with the stark reality that their deteriorating vision makes it difficult to maintain the active lifestyle they once had. Keeping older adults with eye disease as mobile as possible may help prevent

morbidity associated with a sedentary lifestyle, mobility disability and ultimately mortality in this vulnerable population.

**Table 1: Description of four study groups**

|   | <i>AMD<br/>Mean<br/>(SD) or %<br/>n=61</i> | <i>Fuchs<br/>Mean<br/>(SD) or %<br/>n=45</i> | <i>Glaucoma<br/>Mean (SD)<br/>or %<br/>n=79</i> | <i>Controls<br/>Mean (SD)<br/>or %<br/>n=68</i> | <i>P-value</i> |
|---|--|--|---|---|----------------|
| Age   | 82.8 (5.4)                                 | 79.1 (7.0)                                   | 76.7 (7.5)                                      | 72.8 (4.7)                                      | <0.001         |
| Female gender                                       | 79%  | 84%  | 57%   | 65%   | 0.001          |
| Caucasian   | 100%                                       | 100%   | 87%   | 99%   | <0.001         |
| African descent                                     | 0%   | 0%   | 13%   | 1%  |                |
| Obese   | 17%  | 20%  | 22%   | 15%   | 0.729          |
| Binocular visual acuity, letters correct            | 48.7 (19.4)                                | 53.0 (15.0)                                  | 68.4 (16.0)                                     | 82.8 (3.2)                                      | <0.001         |
| Binocular visual acuity, logMAR                     | 0.73 (0.39)                                | 0.64 (0.30)                                  | 0.33 (0.32)                                     | 0.04 (0.06)                                     | <0.001         |
| Contrast sensitivity in better eye, letters correct | 24.8 (7.9)                                 | 25.7 (7.0)                                   | 28.9 (7.6)                                      | 39.2 (2.8)                                      | <0.001         |
| Visual field in better eye, MD                      | -3.2 (3.9)                                 | -3.0 (3.9)                                   | -9.6 (6.7)                                      | 0.5 (2.1)                                       | <0.001         |
| Mini-Mental Blind Version (max 22)                  | 18.9 (2.8)                                 | 19.6 (2.5)                                   | 19.1 (2.9)                                      | 20.8 (1.4)                                      | <0.001         |
| Depressive symptoms                                 | 3.6 (2.9)                                  | 3.3 (2.7)                                    | 2.6 (2.5)                                       | 1.3 (1.8)                                       | <0.001         |
| Comorbidity Score                                   | 3.3 (2.0)                                  | 2.7 (1.7)                                    | 2.6 (1.6)                                       | 2.0 (1.5)                                       | <0.001         |
| Benzodiazepine Use                                  | 36%  | 35%  | 18%   | 15%   | 0.009          |

AMD=age-related macular degeneration

**Table 2: Unadjusted mobility scores of four groups**

|                     | <i>AMD</i><br><i>Mean (SD)</i><br><i>or %</i><br><i>n=61</i> | <i>Fuchs</i><br><i>Mean (SD)</i><br><i>or %</i><br><i>n=45</i> | <i>Glaucoma</i><br><i>Mean (SD)</i><br><i>or %</i><br><i>n=79</i> | <i>Controls</i><br><i>Mean (SD)</i><br><i>or %</i><br><i>n=68</i> | <i>P-Value</i> ‡ |
|---------------------|--|--|---|---|------------------|
| Life Space          | 37.61(17.73)   | 47.14(24.44)   | 54.28(25.72)  | 72.21(18.88)  | <0.001           |
| Poor Balance*       | 65%  | 43%  | 54%   | 22%   | <0.001           |
| TUG time†           | 13.6 (4.9)   | 13.3 (5.7)   | 12.8 (6.0)  | 9.6 (2.2)   | <0.001           |
| Fallen in last year | 30%  | 27%  | 37%   | 22%   | 0.265            |

AMD=age-related macular degeneration; TUG=timed Up and Go

\*includes the 204 people who agreed to perform the balance test. 48 people did not participate due to safety concerns, use of wheelchair or walker, or non-safety concerns such as pain. For 1 person, the reason for non-participation is missing.

†includes the 233 people who performed the TUG. 20 people did not participate due to safety concerns or refusal.

‡ p-value is from ANOVA (continuous variables) or chi-square tests (categorical variables)



**Table 3: Linear regression results on adjusted relationship between eye disease and continuous mobility outcomes.**

|                    | <i>Life Space</i> |                | <i>TUG Time</i> |                |
|--------------------|-------------------|----------------|-----------------|----------------|
|                    | $\beta$           | <i>P-value</i> | $\beta$         | <i>P-value</i> |
| Control            | 0.00              |                | 0.00            |                |
| AMD                | -14.66            | 0.001          | -0.20           | 0.832          |
| Fuchs Dystrophy    | -11.66            | 0.006          | 1.41            | 0.123          |
| Glaucoma           | -10.78            | 0.002          | 1.64            | 0.026          |
| Age                | -0.85             | <0.001         | 0.25            | <0.001         |
| Female Gender      | -11.07            | <0.001         | 1.73            | 0.006          |
| Education          | 0.51              | 0.157          | -0.04           | 0.565          |
| Obese              | -2.08             | 0.549          | 1.89            | 0.014          |
| MMSE Blind Version | 0.81              | 0.164          | -0.17           | 0.215          |
| Depression         | -12.94            | <0.001         | 0.59            | 0.398          |
| Comorbidity Score  | -2.08             | 0.019          | 0.28            | 0.152          |
| Benzodiazepine Use | 2.34              | 0.486          | -0.09           | 0.898          |

CI=confidence interval; AMD=age-related macular degeneration; TUG=timed Up and Go

**Table 4: Logistic regression results on adjusted relationship between eye disease and dichotomous mobility outcomes.**

|                    | <i>Poor Balance</i> |                | <i>Fallen in Last Year</i> |                |
|--------------------|---------------------|----------------|----------------------------|----------------|
|                    | <i>OR</i>           | <i>P-value</i> | <i>OR</i>                  | <i>P-value</i> |
| Control            | 1.00                |                | 1.00                       |                |
| AMD                | 1.23                | 0.742          | 1.07                       | 0.901          |
| Fuchs              | 1.45                | 0.561          | 1.09                       | 0.877          |
| Glaucoma           | 4.10                | 0.005          | 1.79                       | 0.172          |
| Age                | 1.22                | <0.001         | 1.00                       | 0.961          |
| Female Gender      | 2.10                | 0.086          | 1.27                       | 0.514          |
| Education          | 0.91                | 0.073          | 0.94                       | 0.187          |
| Obese              | 0.70                | 0.489          | 0.75                       | 0.509          |
| MMSE Blind Version | 1.16                | 0.081          | 1.05                       | 0.520          |
| Depression         | 4.02                | 0.004          | 2.30                       | 0.021          |
| Comorbidity Score  | 1.12                | 0.385          | 0.97                       | 0.775          |
| Benzodiazepine Use | 0.69                | 0.461          | 0.96                       | 0.923          |

OR=odds ratio; CI=confidence interval; AMD=age-related macular degeneration; BMI= body mass index;

## **CHAPTER V                      DISCUSSION**

The general objective of this Master's thesis was to determine if older patients with eye diseases are more likely to have mobility limitations. The hypothesis tested was that patients with eye disease such as age-related macular degeneration, glaucoma, or Fuchs corneal dystrophy would have reduced mobility and that their mobility would be limited in different ways depending on the type of eye disease. Several points related to the results have been discussed in the manuscript in Chapter IV. This discussion will elaborate more on the results and is divided into three sections. The first section summarizes the findings on the association between eye disease and mobility. The second section presents the strengths and limitations of the study in more detail. Finally, the third section addresses the clinical implications of the results and the need to conduct future longitudinal research on this topic in order to be able to examine the temporal relationship between the onset of eye disease and the loss of mobility.

### **V.1. Eye Disease and Mobility Loss**

This study provides evidence that patients with eye diseases such as age-related macular degeneration, glaucoma, or Fuchs corneal dystrophy all had mobility restrictions. However, in terms of the types of mobility that were impaired – life space, timed Up and Go (TUG) test, balance, or falls – the groups were affected differently.

Life space scores were lowest in the patients with AMD as they were 15 points lower than control patients, on average. However, there was a range of life space scores among AMD patients as the scores ranged from a low of 9 to a high of 92. The strong relationship between AMD and life space is primarily explained by the driving status of the patient. When driving status is entered into the regression model, the association between AMD and life space is cut in half but it is still statistically significant. Glaucoma and Fuchs patients also had reduced life space

scores that were 12 and 11 points lower than those of controls. The value of the life space questionnaire is that it gives a summary of how mobile a person is in the community and it combines information on driving, social support, walking ability, and balance. Clearly, patients with the eye diseases in this study are not as mobile as control patients with good vision.

In contrast, patients with glaucoma suffered from decrements in both dynamic and static balance while patients with AMD and Fuchs did not. It is known from other literature that visual field is important to postural sway and balance. Other measures of visual function that were not examined in the present study may also be important to balance, such as motion detection threshold, which is the ability to detect small movements.<sup>82</sup> For a test that took control patients 10 seconds on average to perform, it took the glaucoma patients 16% longer. If one imagines all the dynamic balance tasks that one performs over the course of a day, this could translate into substantially decreased function. Similarly, glaucoma patients had 4.1 times the odds of having poor balance, which was defined as being unable to hold the one-legged stand for 5 seconds. Patients with glaucoma may not realize that they are at risk for difficulties with balance, especially if their central vision is still good.

Surprisingly, no associations were found between eye disease and falls during the year preceding the interview. No associations were found when examining injurious falls or fall number. This was unexpected and could be due to the measurement of falls, which was based on self-report, or due to compensatory strategies used by patients with eye disease that may lower the risk of falls. Older adults routinely use compensatory strategies when faced with decreased functional abilities. For example, they may reduce their life space; they may restrict their driving; they may use a mobility aid; or they may change their gait. All these compensatory strategies could affect the risk of having a fall. This study was not focused on compensatory strategies, but further research could examine the use of compensatory strategies in patients with eye disease.

One goal of the present study was to determine which measure of visual function (VA, CS, or VF) best explains the relationship between eye disease and mobility limitations. Interestingly, contrast sensitivity was the measure of visual

function that most explained the relationships between all three eye diseases and life space. Contrast sensitivity has been previously found to be important for car crashes<sup>83</sup> and falls<sup>63</sup>, but many studies do not include a measure of contrast sensitivity, preferring instead to only measure visual acuity. Visual field impairment best explained the relationship between worse TUG score and balance in glaucoma patients. This concurs with what is known about the importance of visual field and postural stability.<sup>56</sup>

The other factors that were important in this study included depression, obesity, comorbidity, and gender. Screening for depression using the GDS-15, it was found that one-quarter of the cohort met the criteria for depression. Patients with depressive symptoms had lower life space, worse balance, and were more likely to have fallen. Patients who were obese had a longer TUG time. Patients with more comorbidity had more restricted life space. Women had reduced life space and longer TUG times.

## **V.2. Strengths and Limits of the Study**

This study was novel in its recruitment of patients with three different eye diseases compared to a control group with good vision in order to compare a wide variety of both questionnaire and performance-based mobility measures. No studies have been done to examine the mobility of patients with Fuchs corneal dystrophy. Mobility was assessed using standardized and validated instruments. The mobility chosen measures are important for independent living. Data on potential confounders such as age, gender, chronic health conditions, body mass index, depression, educational attainment, cognitive status, and benzodiazepine use were also collected. All potential patients were approached and response rate was recorded. There was a representative sample of eligible patients from the clinic. There was a 71% response rate in this study.

There are some limitations of the study. Because it was cross-sectional, one cannot make any assumptions regarding the temporality of the onset of eye disease

and the onset of mobility loss. A longitudinal design would have offered more insight in ascertaining the temporal order of circumstances surrounding the mobility loss and would allow examination of the trajectory of mobility loss over time. One concern about the inability to show temporality is the risk of reverse causality. It was hypothesized that patients with eye disease must reduce their mobility because of their vision. However, it is also possible that patients who develop mobility limitations due to other factors then go on to develop more severe eye disease due to an inability to properly care for the eyes. For example, a patient confined to a wheelchair without adequate social support may develop more severe glaucoma because he cannot get to the clinic to be examined and to be given proper treatment. This is why longitudinal data are needed to properly establish temporal relationships.

Another limitation is the generalizability of the findings beyond the population who match the characteristics of those patients in this study. These patients all had bilateral eye disease of a certain severity and had fairly good cognitive scores to allow them to answer the questionnaires. The patients all attended one tertiary care clinic in Montreal and were predominantly of Caucasian ethnicity. Whether the findings generalize to other ethnic groups and hospitals is not known.

Another limitation is usage of self-reported data regarding life-space and falls. The advantage of self-reported data is that it is easy to obtain, compared to asking patients to keep a diary or obtaining health records for an injurious fall. However, the disadvantage is that self-reported data can be misclassified due to problems with memory or lack of honesty. Recall bias may explain why falls during the year preceding the interview were not related with mobility limitations, since falls tend to be forgotten if they are non-injurious.<sup>33</sup> Also, under-reporting of falls might have occurred because of a reluctance to admit falling, because of fear that recognizing it could be a sign of aging. Recall bias can result in nondifferential misclassification which can bias results to the null, which could explain the negative findings for falls.

Finally, another limitation was the relatively small size (n=45) of the Fuchs corneal dystrophy group. There was only 58% power to detect the relationship between Fuchs and an increased average TUG time of 1.4 seconds with 45 patients.

If the target number of 80 patients had been recruited, there would have had 71% power to detect this association or 82% power to detect an increased TUG time of 1.6 seconds. However, despite the smaller size of the Fuchs group, there was still a statistically significant association between Fuchs and life space.

### **V.3. Clinical Implications and Future Research**

This study is the first step in identifying the mobility limitations of patients with eye disease. It makes an important contribution to the knowledge of patients, their families, and their physicians. Patients with eye disease may benefit from knowledge that their balance may be affected. They may use this knowledge to take steps to protect themselves. Families of patients may also find this information beneficial. They may take steps to make the living environment of the patient with eye disease more secure and may try to be more available for accompanying patients with eye disease on trips. Finally, low vision rehabilitation providers may find this study useful in order to better help patients with eye disease deal with mobility limitations like impaired balance or reduced life space. Moreover, older adults with eye disease may benefit from a comprehensive geriatric evaluation and the elaboration of a treatment plan to address modifiable non-visual risk factors for mobility problems like benzodiazepine use.

This study provides a scientific rationale for future longitudinal investigations to examine the trajectory of mobility loss over time and to learn whether mobility limitations such the ones studied are preventable in patients with eye disease.

**Table 1: Non-visual risk factors for mobility limitations**

| <b>Category of risk factors</b> | <b>Subsystems</b>   |
|---------------------------------|---|
| <b>Demographic</b>              | Age - older age <sup>2, 84</sup><br>Gender - female gender <sup>81</sup><br>Marital status - single marital status <sup>2</sup><br>Social economic status - low income, less than 25.000 per year (inaccessibility to transportation, fitness classes, mobility aid devices) <sup>2</sup><br>Educational level - less than high school education <sup>2</sup> |
| <b>Comorbidities</b>            | Cognitive status <sup>85, 86</sup><br>Muscles mass, power and strength <sup>87</sup><br>Bone and joints integrity <sup>88</sup><br>Cardio-vascular disease <sup>88, 89</sup><br>Respiratory function <sup>88</sup><br>Acute illness <sup>88</sup>   |
| <b>Lifestyle factors</b>        | Smoking <sup>90</sup><br>Obesity (BMI>30) <sup>91, 92</sup><br>Sedentary lifestyle <sup>86</sup><br>Driving <sup>93</sup>   |
| <b>Psychosocial</b>             | Depression <sup>94</sup><br>Falls and fear of falling <sup>30, 95</sup><br>Interpersonal dependency <sup>96</sup><br>Social relationships <sup>97</sup>   |



**FIGURE 1.a. Life Space Assessment - English version**<sup>20</sup>

|   |     |    |                              |                 |                 |       |  |  |
|---|-----|----|------------------------------|-----------------|-----------------|-------|--|--|
| Name:   |     |    |                              |                 |                 | Date: |  |  |
| These questions refer to your activity just within the past month.  |     |    |                              |                 |                 |       |  |  |
| <b>LIFE-SPACE LEVEL</b>   |     |    | <b>FREQUENCY</b>             |                 |                 |       | <b>INDEPENDENCE</b>  | <b>SCORE</b>                                 |
| During the past four weeks, have you been to ...  |     |    | How often did you get there? |                 |                 |       | Did you use aids or equipment?<br>Did you need help from another person?             | Level<br>X<br>Frequency<br>X<br>Independence |
| <b>Life-space level 1 ...</b><br>Other rooms of your home besides the room where you sleep?   | Yes | No | Less than 1 /week            | 1-3 times /week | 4-6 times /week | Daily | 1=Personal assistance<br>1.5=Equipment only<br>2=No equipment or personal assistance |  |
|   | 1   | 0  | 1                            | 2               | 3               | 4     |  |  |
| Score   | X   |    | X                            |                 |                 |       | =  | <b>Level 1 Score</b>                         |
| <b>Life-space level 2 ...</b><br>An area outside your home such as your porch, deck or patio, hallway (of an apartment building) or garage, in your own yard or driveway? | Yes | No | Less than 1 /week            | 1-3 times /week | 4-6 times /week | Daily | 1=Personal assistance<br>1.5=Equipment only<br>2=No equipment or personal assistance |  |
|   | 2   | 0  | 1                            | 2               | 3               | 4     |  |  |
| Score   | X   |    | X                            |                 |                 |       | =  | <b>Level 2 Score</b>                         |
| <b>Life-space level 3 ...</b><br>Places in your neighbourhood, other than your own yard or apartment building?  | Yes | No | Less than 1 /week            | 1-3 times /week | 4-6 times /week | Daily | 1=Personal assistance<br>1.5=Equipment only<br>2=No equipment or personal assistance |  |
|   | 3   | 0  | 1                            | 2               | 3               | 4     |  |  |
| Score   | X   |    | X                            |                 |                 |       | =  | <b>Level 3 Score</b>                         |
| <b>Life-space level 4 ...</b><br>Places outside your neighbourhood, but within your town?   | Yes | No | Less than 1 /week            | 1-3 times /week | 4-6 times /week | Daily | 1=Personal assistance<br>1.5=Equipment only<br>2=No equipment or personal assistance |  |
|   | 4   | 0  | 1                            | 2               | 3               | 4     |  |  |
| Score   | X   |    | X                            |                 |                 |       | =  | <b>Level 4 Score</b>                         |
| <b>Life-space level 5 ...</b><br>Places outside your town?  | Yes | No | Less than 1 /week            | 1-3 times /week | 4-6 times /week | Daily | 1=Personal assistance<br>1.5=Equipment only<br>2=No equipment or personal assistance |  |
|   | 5   | 0  | 1                            | 2               | 3               | 4     |  |  |
| Score   | X   |    | X                            |                 |                 |       | =  | <b>Level 5 Score</b>                         |
| <b>TOTAL SCORE (ADD)</b>  |     |    |                              |                 |                 |       |  | <b>Sum of levels</b>                         |

**FIGURE 1.b. Life Space Assessment - French version**<sup>22</sup>

| LES QUESTIONS SUIVANTES CONCERNENT SEULEMENT VOS ACTIVITÉS DU DERNIER MOIS. AU COURS DES QUATRE DERNIÈRES SEMAINES, ÊTES-VOUS ALLÉ ...  | A. AU COURS DES QUATRE DERNIÈRES SEMAINES, COMBIEN DE FOIS ÊTES-VOUS ALLÉ...? |     |                          |                    |                    |                | COMMENT VOUS Y ÊTES-VOUS RENDU? |     |  |               |     |  |
|---|---|-----|--------------------------|--------------------|--------------------|----------------|---------------------------------|-----|--|---------------|-----|--|
|   | Oui   | Non | Moins de 1 fois par sem. | 1 à 3 fois par sem | 4 à 6 fois par sem | Tous les jours | Oui                             | Non | Ne sait pas OU préfère ne pas répondre | Oui           | Non | Ne sait pas OU préfère ne pas répondre |
| DANS DES PIÈCES DE VOTRE DOMICILE, AUTRES QUE CELLE OÙ VOUS DORMEZ? <b>AIRE DE MOBILITÉ 1</b>   | O   | O   | O                        | O                  | O                  | O              | O                               | O   | O                                      | O             | O   | O                                      |
|   | <b>(LS1)</b>  |     | <b>(LS1F)</b>            |                    |                    |                | <b>(LS1A)</b>                   |     |  | <b>(LS1H)</b> |     |  |
| AUTOUR DE VOTRE DOMICILE, comme sur votre galerie, votre balcon, votre terrasse, dans les couloirs (immeuble d'habitation), dans le garage, sur votre terrain ou dans votre entrée de cour? <b>AIRE DE MOBILITÉ 2</b> | O   | O   | O                        | O                  | O                  | O              | O                               | O   | O                                      | O             | O   | O                                      |
|   | <b>(LS2)</b>  |     | <b>(LS2F)</b>            |                    |                    |                | <b>(LS2A)</b>                   |     |  | <b>(LS2H)</b> |     |  |
| DANS VOTRE VOISINAGE, au-delà de votre cour ou de votre immeuble d'habitation? <b>AIRE DE MOBILITÉ 3</b>  | O   | O   | O                        | O                  | O                  | O              | O                               | O   | O                                      | O             | O   | O                                      |
|   | <b>(LS3)</b>  |     | <b>(LS3F)</b>            |                    |                    |                | <b>(LS3A)</b>                   |     |  | <b>(LS3H)</b> |     |  |
| DANS VOTRE VILLE, au-delà de votre voisinage? <b>AIRE DE MOBILITÉ 4</b>   | O   | O   | O                        | O                  | O                  | O              | O                               | O   | O                                      | O             | O   | O                                      |
|   | <b>(LS4)</b>  |     | <b>(LS4F)</b>            |                    |                    |                | <b>(LS4A)</b>                   |     |  | <b>(LS4H)</b> |     |  |
| À L'EXTÉRIEUR DE VOTRE VILLE? <b>AIRE DE MOBILITÉ 5</b>   | O   | O   | O                        | O                  | O                  | O              | O                               | O   | O                                      | O             | O   | O                                      |
|   | <b>(LS5)</b>  |     | <b>(LS5F)</b>            |                    |                    |                | <b>(LS5A)</b>                   |     |  | <b>(LS5H)</b> |     |  |

1. Guralnik JM, LaCroix AZ, Abbott RD, et al. Maintaining mobility in late life. I. Demographic characteristics and chronic conditions. *Am J Epidemiol*. Apr 15 1993;137(8):845-857.
2. Shumway-Cook A, Ciol MA, Yorkston KM, Hoffman JM, Chan L. Mobility limitations in the Medicare population: prevalence and sociodemographic and clinical correlates. *J Am Geriatr Soc*. Jul 2005;53(7):1217-1221.
3. Canada Statistics. Profile of disability among adults. 2001; <http://www.statcan.gc.ca/pub/89-577-x/4065022-eng.htm>. Accessed 16 Sep., 2010.
4. Black A, Wood J. Vision and falls. *Clin Exp Optom*. Jul 2005;88(4):212-222.
5. West CG GG, Haegerstrom-Portnoy G, Schneck ME, Lott L, Brabyn JA. Is vision function related to physical functional ability in older adults? *J Am Geriatr Soc*. 2002;Jan 50(1):136-145.
6. Owsley C, McGwin G, Jr., Sloane M, Wells J, Stalvey BT, Gauthreaux S. Impact of cataract surgery on motor vehicle crash involvement by older adults. *JAMA*. Aug 21 2002;288(7):841-849.
7. Canada Stastics. Population by sex and age group, by province and territory 2009. <http://www40.statcan.gc.ca/l01/cst01/demo31a-eng.htm>. Accessed 16 Sep, 2010.
8. Institut de la statistique Québec. Population par année d'âge et par sexe, Québec, 1er juillet 2009. [http://www.stat.gouv.qc.ca/donstat/societe/demographie/struc\\_poplt/201\\_09.htm](http://www.stat.gouv.qc.ca/donstat/societe/demographie/struc_poplt/201_09.htm). Accessed 16 Sep, 2010.
9. Québec. Quebec Portal. Portrait of Quebec. Demography. <http://www.gouv.qc.ca/portail/quebec/pgs/commun/portrait/demographie/?lang=en#Vieillissement>. Accessed 16 Sep, 2010.
10. Guralnik JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. *N Engl J Med*. Mar 2 1995;332(9):556-561.

11. Newman AB, Simonsick EM, Naydeck BL, et al. Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. *JAMA*. May 3 2006;295(17):2018-2026.
12. Van Rensbergen G, Nawrot T. Medical conditions of nursing home admissions. *BMC Geriatr*. 2010;10:46.
13. Howe TE, Rochester L, Jackson A, Banks PM, Blair VA. Exercise for improving balance in older people. *Cochrane Database Syst Rev*. 2007(4):CD004963.
14. Virgili G, Rubin G. Orientation and mobility training for adults with low vision. *Cochrane Database Syst Rev*. 2010(5):CD003925.
15. Stelmack JA, Tang XC, Reda DJ, Rinne S, Mancil RM, Massof RW. Outcomes of the Veterans Affairs Low Vision Intervention Trial (LOVIT). *Arch Ophthalmol*. May 2008;126(5):608-617.
16. Webber SC, Porter MM, Menec VH. Mobility in older adults: a comprehensive framework. *Gerontologist*. Aug 2010;50(4):443-450.
17. May D, Nayak US, Isaacs B. The life-space diary: a measure of mobility in old people at home. *Int Rehabil Med*. 1985;7(4):182-186.
18. Tinetti ME, Ginter SF. The nursing home life-space diameter. A measure of extent and frequency of mobility among nursing home residents. *J Am Geriatr Soc*. Dec 1990;38(12):1311-1315.
19. Stalvey BT, Owsley C, Sloane ME, Ball K. The Life Space Questionnaire: a Measure of the Extent of Mobility of Older Adults. *Journal of Applied Gerontology*. Dec 1999;18(4):460-478.
20. Baker PS, Bodner EV, Allman RM. Measuring life-space mobility in community-dwelling older adults. *J Am Geriatr Soc*. Nov 2003;51(11):1610-1614.
21. Peel C, Sawyer Baker P, Roth DL, Brown CJ, Brodner EV, Allman RM. Assessing mobility in older adults: the UAB Study of Aging Life-Space Assessment. *Phys Ther*. Oct 2005;85(10):1008-1119.
22. Auger C, Demers L, Gelinias I, et al. Development of a French-Canadian version of the Life-Space Assessment (LSA-F): content validity, reliability

- and applicability for power mobility device users. *Disabil Rehabil Assist Technol*. Jan 2009;4(1):31-41.
23. Barnes LL, Wilson RS, Bienias JL, et al. Correlates of life space in a volunteer cohort of older adults. *Exp Aging Res*. Jan-Mar 2007;33(1):77-93.
  24. Mathias S, Nayak US, Isaacs B. Balance in elderly patients: the "get-up and go" test. *Arch Phys Med Rehabil*. Jun 1986;67(6):387-389.
  25. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. *J Am Geriatr Soc*. Feb 1991;39(2):142-148.
  26. Shumway-Cook A BS, Woollacott M. Predicting the probability for falls in community-dwelling older adults using the Timed Up & Go Test. *Phys Ther*. 2000;Sep 2000;80(9):896-903.
  27. Bischoff HA, Stahelin HB, Monsch AU, et al. Identifying a cut-off point for normal mobility: a comparison of the timed 'up and go' test in community-dwelling and institutionalised elderly women. *Age Ageing*. May 2003;32(3):315-320.
  28. Jonsson E, Seiger A, Hirschfeld H. One-leg stance in healthy young and elderly adults: a measure of postural steadiness? *Clin Biomech (Bristol, Avon)*. Aug 2004;19(7):688-694.
  29. Vellas BJ, Wayne SJ, Romero L, Baumgartner RN, Rubenstein LZ, Garry PJ. One-leg balance is an important predictor of injurious falls in older persons. *J Am Geriatr Soc*. Jun 1997;45(6):735-738.
  30. Maki BE, Holliday PJ, Topper AK. A prospective study of postural balance and risk of falling in an ambulatory and independent elderly population. *J Gerontol*. Mar 1994;49(2):M72-84.
  31. Michikawa T, Nishiwaki Y, Takebayashi T, Toyama Y. One-leg standing test for elderly populations. *J Orthop Sci*. Sep 2009;14(5):675-685.
  32. Blake AJ MK, Bendall MJ, Dallosso H, Ebrahim SB, Arie TH, Fentem PH, Bassej EJ. Falls by elderly people at home: prevalence and associated factors. *Age Ageing* 1988; Nov.17(6):365-372.
  33. Cummings SR, Nevitt MC, Kidd S. Forgetting falls. The limited accuracy of recall of falls in the elderly. *J Am Geriatr Soc*. Jul 1988;36(7):613-616.

34. Sattin RW, Lambert Huber DA, DeVito CA, et al. The incidence of fall injury events among the elderly in a defined population. *Am J Epidemiol*. Jun 1990;131(6):1028-1037.
35. Tinetti ME, Williams CS. Falls, injuries due to falls, and the risk of admission to a nursing home. *N Engl J Med*. Oct 30 1997;337(18):1279-1284.
36. Campbell AJ, Borrie MJ, Spears GF, Jackson SL, Brown JS, Fitzgerald JL. Circumstances and consequences of falls experienced by a community population 70 years and over during a prospective study. *Age Ageing*. Mar 1990;19(2):136-141.
37. Howland J, Peterson EW, Levin WC, Fried L, Pordon D, Bak S. Fear of falling among the community-dwelling elderly. *J Aging Health*. May 1993;5(2):229-243.
38. Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. *J Gerontol*. Mar 1994;49(2):M85-94.
39. Chang M, Cohen-Mansfield J, Ferrucci L, et al. Incidence of loss of ability to walk 400 meters in a functionally limited older population. *J Am Geriatr Soc*. Dec 2004;52(12):2094-2098.
40. WHO. Glaucoma is second leading cause of blindness globally. 2004; <http://www.who.int/bulletin/volumes/82/11/en/infocus.pdf>. Accessed 29 Oct., 2010.
41. Perruccio AV, Badley EM, Trope GE. Self-reported glaucoma in Canada: findings from population-based surveys, 1994-2003. *Can J Ophthalmol*. Apr 2007;42(2):219-226.
42. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. *JAMA*. Jul 17 1991;266(3):369-374.
43. The National Coalition for Vision Health. Data and Statistics. 2008; <http://www.visionhealth.ca/data.htm#Eye%20Diseases>. Accessed 19 Sep., 2010.

44. Hawkins BS, Bird A, Klein R, West SK. Epidemiology of age-related macular degeneration. *Mol Vis*. Nov 3 1999;5:26.
45. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. *Surv Ophthalmol*. May-Jun 2003;48(3):257-293.
46. AREDS. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. *Arch Ophthalmol*. 2001;119(10):1417-1436.
47. Bergmanson JP, Sheldon TM, Goosey JD. Fuchs' endothelial dystrophy: a fresh look at an aging disease. *Ophthalmic Physiol Opt*. May 1999;19(3):210-222.
48. Price MO, Giebel AW, Fairchild KM, Price FW, Jr. Descemet's membrane endothelial keratoplasty: prospective multicenter study of visual and refractive outcomes and endothelial survival. *Ophthalmology*. Dec 2009;116(12):2361-2368.
49. Rasouli M, Caraiscos VB, Slomovic AR. Efficacy of Routine Notification and Request on reducing corneal transplantation wait times in Canada. *Can J Ophthalmol*. Feb 2009;44(1):31-35.
50. Visual Impairments: Determining Eligibility for Social Security Benefits. Washington DC: National research Council;2002.
51. Rubin GS, West SK, Munoz B, et al. A comprehensive assessment of visual impairment in a population of older Americans. The SEE Study. Salisbury Eye Evaluation Project. *Invest Ophthalmol Vis Sci*. Mar 1997;38(3):557-568.
52. Wall M, Neahring RK, Woodward KR. Sensitivity and specificity of frequency doubling perimetry in neuro-ophthalmic disorders: a comparison with conventional automated perimetry. *Invest Ophthalmol Vis Sci*. Apr 2002;43(4):1277-1283.
53. Turano KA, Rubin GS, Quigley HA. Mobility performance in glaucoma. *Invest Ophthalmol Vis Sci*. Nov 1999;40(12):2803-2809.

54. Friedman DS, Freeman E, Munoz B, Jampel HD, West SK. Glaucoma and mobility performance: the Salisbury Eye Evaluation Project. *Ophthalmology*. Dec 2007;114(12):2232-2237.
55. Shabana N, Cornilleau-Peres V, Droulez J, Goh JC, Lee GS, Chew PT. Postural stability in primary open angle glaucoma. *Clin Experiment Ophthalmol*. Jun 2005;33(3):264-273.
56. Black AA, Wood JM, Lovie-Kitchin JE, Newman BM. Visual impairment and postural sway among older adults with glaucoma. *Optom Vis Sci*. Jun 2008;85(6):489-497.
57. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains Eye Study. *J Am Geriatr Soc*. Jan 1998;46(1):58-64.
58. Haymes SA, Leblanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Risk of falls and motor vehicle collisions in glaucoma. *Invest Ophthalmol Vis Sci*. Mar 2007;48(3):1149-1155.
59. Wood JM, Lacherez PF, Black AA, Cole MH, Boon MY, Kerr GK. Postural stability and gait among older adults with age-related maculopathy. *Invest Ophthalmol Vis Sci*. Jan 2009;50(1):482-487.
60. Spaulding SJ, Patla AE, Elliott DB, Flanagan J, Rietdyk S, Brown S. Waterloo Vision and Mobility Study: gait adaptations to altered surfaces in individuals with age-related maculopathy. *Optom Vis Sci*. Dec 1994;71(12):770-777.
61. Cruess A, Zlateva G, Xu X, Rochon S. Burden of illness of neovascular age-related macular degeneration in Canada. *Can J Ophthalmol*. Dec 2007;42(6):836-843.
62. Hassan SE, Lovie-Kitchin JE, Woods RL. Vision and mobility performance of subjects with age-related macular degeneration. *Optom Vis Sci*. Nov 2002;79(11):697-707.
63. Lord SR, Dayhew J. Visual risk factors for falls in older people. *J Am Geriatr Soc*. May 2001;49(5):508-515.



64. Szabo SM, Janssen PA, Khan K, Potter MJ, Lord SR. Older women with age-related macular degeneration have a greater risk of falls: a physiological profile assessment study. *J Am Geriatr Soc.* May 2008;56(5):800-807.
65. Busse A, Sonntag A, Bischkopf J, Matschinger H, Angermeyer MC. Adaptation of dementia screening for vision-impaired older persons: administration of the Mini-Mental State Examination (MMSE). *J Clin Epidemiol.* Sep 2002;55(9):909-915.
66. Rubin GS, Bandeen-Roche K, Huang GH, et al. The association of multiple visual impairments with self-reported visual disability: SEE project. *Invest Ophthalmol Vis Sci.* Jan 2001;42(1):64-72.
67. Sorock GS, Shimkin EE. Benzodiazepine sedatives and the risk of falling in a community-dwelling elderly cohort. *Arch Intern Med.* Nov 1988;148(11):2441-2444.
68. Maxwell CJ, Neutel CI, Hirdes JP. A prospective study of falls after benzodiazepine use: a comparison of new and repeat use. *Pharmacoepidemiol Drug Saf.* Jan 1997;6(1):27-35.
69. Neutel CI, Hirdes JP, Maxwell CJ, Patten SB. New evidence on benzodiazepine use and falls: the time factor. *Age Ageing.* Jul 1996;25(4):273-278.
70. Bourque P, Blanchard, L., & Vézina, J. Étude psychométrique de l'Échelle de dépression gériatrique. *Revue Canadienne du Vieillissement.* 1990;9:348-355.
71. Burke WJ, Roccaforte WH, Wengel SP. The short form of the Geriatric Depression Scale: a comparison with the 30-item form. *J Geriatr Psychiatry Neurol.* Jul-Sep 1991;4(3):173-178.
72. Almeida OP, Almeida SA. Short versions of the geriatric depression scale: a study of their validity for the diagnosis of a major depressive episode according to ICD-10 and DSM-IV. *Int J Geriatr Psychiatry.* Oct 1999;14(10):858-865.
73. Bailey IL, Bullimore MA, Raasch TW, Taylor HR. Clinical grading and the effects of scaling. *Invest Ophthalmol Vis Sci.* Feb 1991;32(2):422-432.

74. Ferris FL, 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. *Am J Ophthalmol*. Jul 1982;94(1):91-96.
75. Elliott DB, Sanderson K, Conkey A. The reliability of the Pelli-Robson contrast sensitivity chart. *Ophthalmic Physiol Opt*. Jan 1990;10(1):21-24.
76. Anderson AJ, Johnson CA. Frequency-doubling technology perimetry. *Ophthalmol Clin North Am*. Jun 2003;16(2):213-225.
77. Freeman E, Broman A, Turano, KA, West, SK. Motion Detection Threshold and Measures of Balance in Older Adults. *Invest Ophthalmol Vis Sci*. 2008;In press.
78. Freeman EE, Munoz B, Rubin G, West SK. Visual field loss increases the risk of falls in older adults: the Salisbury eye evaluation. *Invest Ophthalmol Vis Sci*. Oct 2007;48(10):4445-4450.
79. Coleman AL, Stone K, Ewing SK, et al. Higher risk of multiple falls among elderly women who lose visual acuity. *Ophthalmology*. May 2004;111(5):857-862.
80. Klein BE, Moss SE, Klein R, Lee KE, Cruickshanks KJ. Associations of visual function with physical outcomes and limitations 5 years later in an older population: the Beaver Dam eye study. *Ophthalmology*. Apr 2003;110(4):644-650.
81. Leveille SG, Penninx BW, Melzer D, Izmirlian G, Guralnik JM. Sex differences in the prevalence of mobility disability in old age: the dynamics of incidence, recovery, and mortality. *J Gerontol B Psychol Sci Soc Sci*. Jan 2000;55(1):S41-50.
82. Freeman EE, Munoz B, Turano KA, West SK. Measures of visual function and their association with driving modification in older adults. *Invest Ophthalmol Vis Sci*. Feb 2006;47(2):514-520.
83. Anand V, Buckley JG, Scally A, Elliott DB. Postural stability changes in the elderly with cataract simulation and refractive blur. *Invest Ophthalmol Vis Sci*. Nov 2003;44(11):4670-4675.

84. Allman RM, Baker PS, Maisiak RM, Sims RV, Roseman JM. Racial similarities and differences in predictors of mobility change over eighteen months. *J Gen Intern Med.* Nov 2004;19(11):1118-1126.
85. von Bonsdorff M, Rantanen T, Laukkanen P, Suutama T, Heikkinen E. Mobility limitations and cognitive deficits as predictors of institutionalization among community-dwelling older people. *Gerontology.* 2006;52(6):359-365.
86. Avlund K, Damsgaard MT, Sakari-Rantala R, Laukkanen P, Schroll M. Tiredness in daily activities among nondisabled old people as determinant of onset of disability. *J Clin Epidemiol.* Oct 2002;55(10):965-973.
87. Visser M, Goodpaster BH, Kritchevsky SB, et al. Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. *J Gerontol A Biol Sci Med Sci.* Mar 2005;60(3):324-333.
88. Melzer D, Gardener E, Guralnik JM. Mobility disability in the middle-aged: cross-sectional associations in the English Longitudinal Study of Ageing. *Age Ageing.* Nov 2005;34(6):594-602.
89. Oldridge NB, Stump TE. Heart disease, comorbidity, and activity limitation in community-dwelling elderly. *Eur J Cardiovasc Prev Rehabil.* Oct 2004;11(5):427-434.
90. Ostbye T, Taylor DH, Jr., Krause KM, Van Scoyoc L. The role of smoking and other modifiable lifestyle risk factors in maintaining and restoring lower body mobility in middle-aged and older Americans: results from the HRS and AHEAD. Health and Retirement Study. Asset and Health Dynamics Among the Oldest Old. *J Am Geriatr Soc.* Apr 2002;50(4):691-699.
91. Davison KK, Ford ES, Cogswell ME, Dietz WH. Percentage of body fat and body mass index are associated with mobility limitations in people aged 70 and older from NHANES III. *J Am Geriatr Soc.* Nov 2002;50(11):1802-1809.
92. Jenkins KR. Obesity's effects on the onset of functional impairment among older adults. *Gerontologist.* Apr 2004;44(2):206-216.

93. Campbell MK, Bush TL, Hale WE. Medical conditions associated with driving cessation in community-dwelling, ambulatory elders. *J Gerontol*. Jul 1993;48(4):S230-234.
94. Gayman MD, Turner RJ, Cui M. Physical limitations and depressive symptoms: exploring the nature of the association. *J Gerontol B Psychol Sci Soc Sci*. Jul 2008;63(4):S219-S228.
95. Friedman SM, Munoz B, West SK, Rubin GS, Fried LP. Falls and fear of falling: which comes first? A longitudinal prediction model suggests strategies for primary and secondary prevention. *J Am Geriatr Soc*. Aug 2002;50(8):1329-1335.
96. Gardner DK, Helmes E. Interpersonal dependency in older adults and the risks of developing mood and mobility problems when receiving care at home. *Aging Ment Health*. Jan 2006;10(1):63-68.
97. Mollenkopf H, Marcellini F, Ruoppila I, Flaschentrager P, Gagliardi C, Spazzafumo L. Outdoor mobility and social relationships of elderly people. *Arch Gerontol Geriatr*. May-Jun 1997;24(3):295-310.